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THE ROLE OF PLATELETS IN HYALURONAN DEGRADATION 
SAMI ALBEIROTI 
ABSTRACT 
Following tissue injury, platelets rapidly interact with the exposed extracellular matrix 
(ECM) of blood vessel wall and the surrounding tissues. Hyaluronan (HA) is a major 
polysaccharide component of the ECM and plays a significant role in regulating 
inflammation. Human platelets can degrade HA from the surfaces of activated endothelial 
cells into fragments capable of inducing immune responses by monocytes. In addition, 
platelets contain the enzyme hyaluronidse-2 (HYAL2), one of two major hyaluronidases 
that digest HA in somatic tissues. The deposition of HA increases in the inflamed tissues 
in several inflammatory diseases, including Inflammatory Bowel Disease (IBD). This 
study provides evidence that IBD patients’ platelets have low HYAL2 levels and activity 
and defines the mechanism by which platelets degrade HA in the inflamed tissues. 
Human platelets degrade the pro-inflammatory matrix HA through the activity of 
HYAL2. Importantly, platelet activation causes the immediate translocation of HYAL2 
from a distinct population of α-granules to platelet surfaces, where it exerts its catalytic 
activity. Additionally, platelet activation causes increased binding of platelets to HA. The 
study also shows that platelets express the novel HA-binding protein KIAA1199, which 
they release upon activation. Our data provide a new perspective on how platelets interact 
with their surrounding tissues and explain a possible novel role for platelets in 
inflammation. 
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CHAPTER I 
BACKGROUND 
 
1.1. The Extracellular Matrix 
Although cells represent the major component of living tissues, a significant 
volume of the tissues is occupied by an extracellular space known as the extracellular 
matrix (ECM). A wide variety of molecules constitute the ECM, including proteins and 
polysaccharides. Most of these molecules are organized at the surface of the cells that 
produce them forming a network between cells. The diversity of molecules that form the 
ECM varies depending on tissue type. Whereas the matrix in bones is calcified to 
produce hard structures, the matrix of the cornea is soft and transparent [1,2].  
Aside from its classical role in structure and support, ECM also has a major role 
in cell regulation, including cell function, migration, proliferation and survival. The ECM 
is composed mainly of two types of macromolecules. The first type is the fibrous proteins 
that have roles in both structure and adhesion. These include elastin, which provides 
elasticity; collagen, which forms fibers that provide strength and organization to the 
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matrix; and fibronectin, which assists in cell attachment [1]. The second is a class of large 
polysaccharides, known as glycosaminoglycans (GAGs). The fibrous proteins are 
typically entrenched in a gel-like structure formed by the GAGs. The organization allows 
for the blood and cells to interact readily, aiding in the fast diffusion of molecules. Most 
GAGs exist in proteoglycans, a class of carbohydrates covalently linked to protein cores. 
The only exception is hyaluronan (HA), which does not include a protein as a core 
component [3,4].  
1.1.1 Glycosaminoglycans 
Glycosaminoglycans (GAGs) represent a major constituent of the ECM, although 
they can also be found intracellularly. The name refers to the presence of amino 
monosaccharides and other monosaccharides in a polymeric structure. With the exception 
of HA, GAGs can be sulfated and covalently linked to a protein. This group of 
macromolecules is made up of HA, dermatan sulfate (DS), keratan sulfate (KS), 
chondroitin, chondroitin sulfate (CS), heparin, and heparan sulfate (HS). These 
proteoglycans are composed of a core protein and chains of linear GAGs covalently 
linked to the protein. GAGs are made up of chains of disaccharides; each disaccharide is 
composed of an amino monosaccharide (N-acetylglucosamine, or N-acetylgalactosamine) 
and a non amino monosaccharide (a uronic acid, or galactose). Whereas some 
proteoglycans have only one linked GAG chain, others can have many GAG chains 
attached [5,6].  
GAGs in the ECM demonstrate a wide range of functions. For example, CS and 
DS proteoglycans are extremely hydrophilic, which aides in forming hydrated matrices 
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that occupy the space between cells. The large volume HA occupies in solution creates a 
structure that absorbs compressive loads in cartilage [7]. Basement membrane 
organization is another major function of GAGs [8]; they create a suitable environment 
for epithelial cells to proliferate and differentiate. KS, on the other hand, plays a crucial 
role in the cornea. The special arrangement of KS and collagen in the cornea permits the 
light to pass without dispersion [9].  
Not only do GAGs play a role in structure and support, but they also have 
important regulatory roles. GAGs can bind cytokines and chemokines; they interact with 
growth factors, thus affecting signaling pathways; and they act as receptors for 
endocytosis. In addition, GAGs, in cooperation with adhesion receptors, facilitate the 
interaction between cells as well as cell motility and migration. The interactions between 
GAGs and various protein ligands lead to numerous physiological outcomes. A good 
example is the role heparin plays in anticoagulation. Injected heparin is widely used as an 
anticoagulant due to its binding capacity to antithrombin, resulting in its activation, and 
to P-selectin, resulting in its blockade, which consequently results in anticoagulation [10]. 
1.2. Hyaluronan 
1.2.1. Hyaluronan Structure 
 Hyaluronan (HA) is a ubiquitous, non-sulfated, unbranched GAG and the largest 
polysaccharide produced in vertebrates. It is the only GAG that does not have a core 
protein component. HA chain is made up of repeating disaccharides; each disaccharide is 
composed of D-N-acetylglucosamine and D-glucuronic acid linked by alternating β-(1,4) 
and β-(1,3) glycosidic bonds (figure 1.1). HA can become very large reaching up to 107 
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Dalton.  HA is also highly polyanionic due to the carboxyl groups of the glucuronic acid 
residues, which gives it a random coil structure in solution [11]. One of the most 
important characteristics of HA is its high hydrophilicity, which can result in a very 
viscous environment when water is bound to HA. This property is clearly found in the 
vitreous humor of the eye and in joints, where HA is abundant. For example, HA, in 
synovial fluid of joints, aides in load distribution during motion, in lubrication, and in 
protection of the surfaces of cartilage [12].  
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Figure 1.1: The disaccharide that represents the building block of hyaluronan. 
Hyaluronan is made up of repeating disaccharides of D-N-acetylglucosamine and D-
glucuronic acid linked by alternating β-(1,4) and β-(1,3) glycosidic bonds. N= 2 – 20,000. 
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1.2.2. Hyaluronan synthesis 
 Three mammalian HA synthase enzymes (HAS) have been identified: HAS1, 
HAS2, and HAS3; their structure is well-conserved among various mammalian species. 
Structurally, they contain seven membrane spanning regions: two at the N-terminus and 
five at the C-terminus. Whereas HAS3 synthesizes HA with a size range of 10
5
-10
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Dalton, HAS1 and HAS2 are capable of producing much larger HA polymers. HA is 
synthesized, uniquely and contrary to the other GAGs that are synthesized in the Golgi 
apparatus, at the inner surface of the cell membrane by one of the HAS enzymes, where 
UDP-N-acetylglucosamine and UDP-glucuronic acid are added alternately to the 
reducing end of the HA chain being synthesized. The growing HA molecule then gets 
translocated extracellularly through the membrane by HAS. Studies have shown that 
HAS2 is responsible for the majority of HA synthesis compared to HAS1 and HAS3 and 
that knocking down HAS2 in mice is embryonically lethal due to severe cardiovascular 
defects. On the other hand, HAS1/3 knockout mice develop normally. The activity of 
HAS enzymes can be regulated at the transcriptional level or at the posttranslational level 
by phosphorylation, O-GlcNAcylation, or ubiquitination. HAS activity can also be 
regulated by the cellular content of the UDP- N-acetylglucosamine and UDP-glucuronic 
acid. Another mechanism by which HAS2 is regulated is dimerization. HAS2 can form 
homodimers or heterodimers with HAS3 in the plasma membrane, which can have an 
effect on its activity [13-15].  
1.2.3. HA binding proteins 
7 
 
Under many conditions, HA exists in the body bound to one of its protein 
partners. Most of HA binding proteins contain a motif known as the link module, which 
is a protein fold that binds specifically to HA. The fold is composed of two α-helices and 
two triple-stranded antiparallel β sheets. Both the hydrogen bond, formed between HA 
and the aromatic amino acids of the link module, and the ionic interaction between the 
carboxylic acid groups of the glucuronic acid residues of HA and the positively charged 
amino acid residues of the link module facilitate the binding of HA to its binding proteins 
[16]. HA binding proteins that contain a link module can be either associated with cell 
surface, such as CD44, lymphatic vessel endothelial hyaluronan receptor (LYVE-1), and 
hepatic hyaluronan clearance receptor (HARE), or secreted molecules, such as versican 
and aggrecan. Some HA binding proteins do not have the link module; this list includes 
receptor for HA-mediated motility (RHAMM) and inter-α-trypsin inhibitor (IαI). 
CD44 is a ubiquitously expressed glycoprotein by most mammalian cells and is 
considered the major cell surface receptor for HA. At least 8 isoforms of CD44 have been 
identified, which are encoded by alternate splicing of the CD44 gene. The cytoplasmic 
end of CD44 has a signaling domain, whereas its extracellular domain has the link 
module. It has been shown that the binding capacity of CD44 to high molecular weight 
HA is higher than its capacity to bind low molecular weight HA. Importantly, CD44 can 
respond to HA binding through the interaction of its cytoplasmic tail with many 
regulatory proteins, including kinases and cytoskeletal components [17].  
1.2.4. Hyaluronan catabolism 
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Catabolism of HA in humans occurs by endo-β-N-acetylhexosaminidase enzymes 
known as hyaluronidases (HYALs). The six identified hyaluronidases in mammals are 
clustered on two chromosomes: HYAL1, HYAL2, and HYAL3 are clustered on 
chromosome 3 at 3p21.3, whereas HYAL4, HYALP1, and SPAM-1 are located likewise on 
chromosome 7 at 7q31.3. Out of the six HYAL enzymes, HYAL1 and HYAL2 are the 
only somatically active HA degrading enzymes in humans. HYAL3, although widely 
expressed, does not appear to have HA degrading activity. SPAM1 (Sperm Adhesion 
Molecule), on the other hand, is found only in the sperm and is necessary for fertilization; 
it cleaves HA from the cumulus mass surrounding the ovum, which facilitates the 
penetration of the sperm. HYAL4 shows only chondroitinase activity and HYALP1 is a 
pseudogene that is not translated in humans [18,19].  
1.2.4.1. HYAL1 
HYAL1 was identified as an acid-active enzyme in serum in 1967 by De Salegui 
et al. [20]. However, it was not cloned and sequenced until 1997 by Frost et al. [21]. 
HYAL1 is a 57-kDa protein that is 40% homologous to SPAM1 AND 73% homologous 
to its mouse ortholog. Its catalytic activity results in HA tetrasaccharides as products. 
Interestingly, a genetic deficiency of HYAL1 has been reported in humans and named 
Mucopolysaccharidosis IX. Although patients have a normal phenotype, there is some 
growth retardation, bilateral peri- and intra-articular soft tissue masses and generalized 
cutaneous swelling. Importantly, their level of circulating HA is extremely high and their 
histiocytes are filled with many large membrane-bound vacuoles, suggesting that the 
disease is a lysosomal storage disease and that HYAL1 is a lysosomal enzyme [22]. 
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1.2.4.2. HYAL2 
In 1998, Lepperdinger et al. identified HYAL2 as a lysosomal enzyme after 
expressing green fluorescent protein-tagged HYAL2 in a rat glioma cell line. They also 
showed that whereas HYAL2 protein and mRNA were detected in most human tissues, 
including heart, liver, kidney, and placenta, they were absent from brain tissues. 
Additionally, these studies showed that HYAL2 is an acid-active enzyme with optimum 
activity below pH of 4 and that it is capable of degrading high molecular weight HA into 
about 20-kDa HA polymers. Interestingly, HYAL2 did not further degrade the 20-kDa 
products nor did it degrade 20-kDa HA fragments isolated from vitreous humor [23].  
Later studies on HYAL2 have shown and confirmed, conversely, that HYAL2 is 
in fact a glycosylphosphatidylinositol (GPI)-anchored cell-surface protein. A GPI-
anchored protein is typically attached to the GPI by its carboxyl terminus and is located 
in the outer leaflet of the lipid bilayer facing the extracellular surroundings. Although 
recombinant HYAL2 shows weak activity compared to HYAL1 and SPAM1, significant 
HAase activity can be detected in cells overexpressing the GPI-anchored HYAL2 [24]. 
Additionally, a soluble form of HYAL2, prepared by inserting a stop codon into HYAL2 
cDNA at the position of the GPI-anchor cleavage site, demonstrated similar activity at 
low pH. This activity was significantly decreased by mutating the amino acids 
corresponding to the active site residues known in the bee venom and SPAM1 
hyaluronidases, suggesting that the HAase activity site of HYAL2 is similar to the 
activity sites in other hyaluronidases. However, the soluble form of HYAL2 digested the 
20-kDa HA, in contrast to the previously reported GPI-anchored HYAL2, which was 
incapable of such activity [25].  
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1.2.4.3. HYAL2 as a virus receptor 
 Different non-HA-degrading functions of HYAL2 have been reported. Notably, 
HYAL2 plays a role as a virus receptor. HYAL2 has been shown to act as a cell-entry 
receptor for Jaagsiekte sheep retrovirus (JSRV), a virus that causes lung cancer in sheep 
and goats, and enzootic nasal tumor virus (ENTV), a virus that causes nasal tumors in the 
these animals. The envelope (ENV) proteins of the two retroviruses play two major 
functions: they contribute to tumorogenisis by transforming fibroblasts and epithelial 
cells, and they facilitate the entry of the virus into cells through binding specifically to 
HYAL2, which suggests that HYAL2 may be playing a major role in cell transformation 
and oncogenesis. Importantly, HYAL2 is localized to a lung cancer tumor suppressor 
locus on chromosome 3p21.3. Binding of ENV to HYAL2 likely damages the tumor 
suppression activity of HYAL2, resulting in tumor formation [24-26].  
1.2.4.4. A model for HA degradation 
The turnover of HA occurs in a very rapid rate in the body. HA is present 
normally in high amounts in different bodily tissues and fluids, including the joint, the 
eye vitreous, the umbilical cord, and amniotic fluid. High levels of HA are also present in 
proliferating tissues and tissues undergoing repair. As a result, the rapid catabolism of 
HA, through the activity of HYAL enzymes, represents a major mechanism by which HA 
levels are regulated in the body [27]. Studies have shown that HA degradation is 
dependent upon the classical HA binding receptor CD44 and involves mainly HYAL1 
and HYAL2. 
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Bourguignon et al. have shown that the degradation of HA by HYAL2 is CD44-
dependent. In human breast tumor cell line, they investigated the role of CD44 in HA 
degradation. They showed that the binding of HA to CD44 activates Rho kinase, which, 
in turn, causes the phosphorylation, and activation, of  Na
+
-H
+
 exchanger (NHE1). The 
activity of NHE1 promotes intracellular acidification and creates an acidic extracellular 
matrix environment. The created acidic environment provides optimum condition for 
HYAL2 to degrade HA at the cell surface [28].  
Other studies have also confirmed the role of CD44 in HA degradation. Harada et 
al. thoroughly investigated the roles of HYAL1, HYAL2, HYAL3, and CD44 in the 
degradation of HA in a human embryonic kidney cell line. They found that HYAL1 
cannot degrade HA in cells lacking CD44 and that its activity in cells expressing CD44 is 
primarily intracellular. Conversely, the activity of HYAL2 was strictly extracellular but 
also dependent upon CD44, which exists on the cell surface along with HYAL2. HYAL3, 
on the other hand, demonstrated no hyaluronidase activity [29]. 
In the light of these reports as well as other studies of HA catabolism, the 
accepted model for HA degradation in tissues of vertebrates involves four enzymes: 
HYAL1, HYAL2, and two β-exoglycosidases (figure 1.2). Degradation of HA starts at 
the cell surface. CD44 binds HA extracellularly and mediates the process by creating an 
acidic microenvionment. Then, the acid-active enzyme HYAL2 degrades large HA 
polymers into 20-kDa polymers. These HA products get internalized into the lysosomes, 
where they get degraded by HYAL1 into tetrasaccharides before N-acetyl 
glucosaminidase and glucuronidase enzymes further degrade them into monosaccharides.  
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Figure 1.2. Representation of a proposed model for HA degradation in cells. 
Degradation of HA starts at the cell surface. CD44 binds HA extracellularly and mediates 
the process by creating an acidic microenvionment. Then, the acid-active enzyme 
HYAL2 degrades large HA polymers into 20-kDa polymers. These HA products get 
internalized into the lysosomes, where they get degraded by HYAL1 into tetrasaccharides 
before N-acetyl glucosaminidase and glucuronidase enzymes further degrade them into 
monosaccharides [18]. 
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1.2.4.5. KIAA1199 
Recently, in 2013, a new contributor to HA degradation was discovered. Yoshida 
et al. have reported that KIAA1199, which is a gene related to deafness but with 
unknown function, has a principle role in the binding and the depolymerization of HA. 
The procedure by which the researchers have identified KIAA1199 as a HA degradation-
related protein was remarkable. They first treated cultured human skin fibroblasts with 
various stimulators and monitored HA degradation. They found that histamine treatment 
resulted in increased HA degradation whereas transforming growth factor beta 1 (TGF-
β1) treatment resulted in decreased HA degradation. Then, using microarray analysis, 
they identified 25 genes that were both up-regulated by histamine and down-regulated by 
TGF-β1. After knocking down all of the 25 genes in the cultured cells and monitoring 
HA degradation following each knockdown, they found that knocking down KIAA1199 
resulted in abolished HA degradation [30].  
 Additionally, when KIAA1199 was expressed in cells lacking HA-cleaving 
activity, the transfected cells acquired the ability to cleave HA. Importantly, out of all 
GAGs tested for their binding ability to KIAA1199, only HA demonstrated HA-binding 
activity. The specific binding of KIAA1199 to HA contributed to the catabolism of HA 
via the clathrin-coated pit pathway. To assess the possibility that KIAA1199 plays a role 
in arthritic diseases, which are characterized by reduced concentration of large molecular 
weight HA and accumulation of low molecular weight HA, the researchers compared the 
HA-degrading activity of arthritic synovial fibroblasts to healthy synovial fibroblasts and 
found that arthritic fibroblasts demonstrated higher activity than the healthy ones and that 
this activity was abolished by knocking down KIAA1199 in these cells. Importantly, 
14 
 
KIAA1199 gene expression was significantly higher in synovial tissues of arthritis 
patients compared to non-arthritic controls [30]. In addition, the group has shown that the 
mouse ortholog of KIAA1199 also possess HA binding and degrading activity [31]. 
Many studies have reported that KIAA1199 is also found to be overexpressed in different 
cancers including breast and colorectal cancers [32]. 
1.2.4.6. Non-enzymatic means of HA degradation 
In addition to the enzymatic processes that cleave HA, HA can be degraded by 
oxidation reactions; particularly, by reactive oxygen species (ROS) and free radicals. The 
damaging outcome of ROS is observed in many diseases. For example, ROS, resulting 
from the inflammation of the joints in patients with artithritic diseases, can cause damage 
to the synovial fluid. Specifically, ROS can destroy synovial fluid HA, which is a major 
component of the synovial fluid and contributes to the lubrication and the smooth 
movement of the joint. A reduction in the molecular weight of synovial fluid HA in 
patients with arthritis has been reported in many studies. Ultimately, degraded synovial 
fluid results in stiff and painful joints [33].  
 HA degradation by ROS may also explain the oxidative stress-induced 
submucosal gland cell hypertrophy and hyperplasia observed in chronic bronchitis. 
Casalino-Matsuda et al. have shown that ROS-induced HA depolymerization results in 
the activation of tissue kallikrein, a protease bound to HA in airway submucosa, the 
release of mature epidermal growth factor, and, consequently, the activation of epidermal 
growth factor receptor (EGFR). The activation of EGFR then contributes to the 
development of gland hyperplasia in the airways. Studies from the same group have 
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shown that ROS-induced HA depolymerization results, through a CD44 and EGFR-
dependent pathway, in increased MUC5B, one of the major mucins present in the 
secretions of airways from patients with asthma cystic fibrosis, and chronic obstructive 
pulmonary disease [34].  
 Not only can ROS induce HA fragmentation directly, but it also can contribute to 
HA degradation indirectly. For example, Monzon et al. have shown that ROS can cause 
an increase in the expression and activity of HYAL2 through a p38 MAPK-dependent 
signaling pathway in normal human bronchial epithelial cells. The group has also shown, 
importantly, that in the tracheal tissues and secretions in smokers, who represent a model 
for chronic oxidative stress exposure, HYAL2 is highly expressed, along with an 
increased concentration of low molecular mass HA [35]. 
1.2.5. HA function is size-dependent 
Accumulating evidence from studies published in the last 20 years has confirmed 
that the molecular weight of HA is critical in determining the biochemical and cellular 
roles of HA. An increasing body of literature suggests that different sizes of HA exert a 
wide spectrum of functions [36,37]. In tissues under normal conditions, HA is present in 
its high molecular weight (HMWHA) form with an average size range of 1-5 X 10
6
 
Dalton. HMWHA functions as a structural, hydrating polymer due to its hydrophilic 
properties. Beyond its role as a space filling, lubricating molecule, HMWHA is also 
known to be anti-inflammatory and anti-angiogenic. Also, HMWHA is shown to mediate 
cancer resistance and to prevent cytolysis. Conversely, low molecular weight HA has 
been shown to have pro-inflammatory and pro-angiogenic effects. 
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In their widely publicized report published in Nature, Tian et al. showed that 
extremely large molecular weight HA mediates cancer resistance in naked mole rats. 
Naked mole rats are exceptional rodents as they have a lifespan exceeding 30 years. This 
longevity is thought to be attributed to the fact that naked mole rats are resistant to 
developing cancer. The group reported that fibroblasts from naked mole rats synthesize 
and release a very large molecular weight HA (up to 12 X 10
6
 Dalton), which is more 
than five times larger than HA detected in human and mouse fibroblasts. Additionally, 
they found that the unusually large HA that is accumulating in the animal tissues is due to 
a unique form of the enzyme HAS2 (two asparagine amino acid residues that are 100% 
conserved in mammals were replaced with two serines in the naked mole rat HAS2) and 
to the decreased activity of the enzyme HYAL2. Importantly, knocking down HAS2, or 
overexpressing HYAL2 in these animals made them susceptible to developing tumors 
[38].  
 A size-dependent function of HA in angiogensis has also been reported [39]. It 
has been shown that HMWHA at physiologic concentrations has anti-angiogenic 
properties. Intact HA binds to CD44 on the cell surface, which can block crucial 
intracellular signaling pathways that result in cell proliferation. This effect can prevent 
endothelial cells from proliferating and thus impact angiogensis. On the other hand, 
LMWHA fragments were shown to have pro-angiogenic effects by stimulating 
endothelial cell proliferation. LMWHA can compete with native HMWHA in binding to 
endothelial cell CD44. These small fragments can mediate intracellular signaling 
pathways that facilitate cell proliferation. LMWHA can also stimulate the expression of 
matrix metalloproteinase (MMP) 2 and 9, which assists in cell invasion through ECM 
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barriers to and mediates vessel development and growth. These MMPs can also induce 
angiogensis by activating TGF-β [39]. HA fragments also interact with RHAMM, which 
results in the modification of endothelial cell cytoskeleton, aiding in their migration. 
LMWHA/RHAMM interactions also affect wound healing. Savani et al. have shown that 
endothelial cell motility is dictated by binding of HA to RHAMM [40]. 
1.2.6. HA in inflammation 
Elevated levels of accumulated HA have been observed in many inflammatory 
diseases. For example, high levels of HA in joint tissues of patients with rheumatoid 
arthritis have been reported. Additionally, many studies have reported on the increased 
HA deposition in inflammatory diseases of the liver. Whereas the concentration of HA in 
the healthy liver is low, its concentration significantly increases in fibrotic liver, leading 
to increased levels of serum HA. As a result, the level of circulating HA has been 
proposed as a biomarker for cirrhotic liver disease, for monitoring liver function, for 
assessing liver fibrosis, and for diagnosing chronic viral hepatitis C [41]. HA levels also 
increase in patients with inflammatory diseases of the lung, including asthma [42]. 
Studies have also shown that an upregulation of HA occurs in the intestines of patients 
with Inflammatory Bowel Disease (IBD) [43].  
1.2.6.1 Role of HMWHA in inflammation 
Many reports have shown that HMWHA has a crucial role in regulating 
inflammation and that it has an anti-inflammatory effect, in addition to its function as a 
structural, hydrating polymer. Large HA polymers have a role as molecules that indicate 
the integrity of tissues; they also control the cellular inflammatory responses [44]. 
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HMWHA can protect from T-cell-mediated liver injury and bleomycin-mediated lung 
injury in mice and it can promote the suppressive effects of regulatory CD4+ CD25+ T 
cells [45-47]. 
Nakamura et al. have shown that HMWHA, and not LMWHA, can prevent T-
cell-mediated liver injury by decreasing proinflammatory cytokines. The group injected 
mice with different sizes of HA ranging from 250 to 1200 kDa before inducing liver 
injury by administrating the mice with concanavalin A, which induces a T-cell mediated 
liver injury and affects the production of cytokines. They found that pretreatment with 
HMWHA, specifically, decreased the levels of alanine aminotransferase in plasma that 
were elevated due to injury. Additionally, they found that HMWHA treatment also 
decreased cytokine levels, including tumor necrosis factor-alpha (TNF-α) and interlukin 
4, and chemokine levels, including macrophage inflammatory protein 2. Collectively, the 
researchers concluded that HMWHA plays a protective effect and can prevent T-cell-
mediated liver injury [45]. 
In their 2002 report in the journal Science, Teder et al. showed that HMWHA and 
its binding partner CD44 have a protective role against lung inflammation. The group has 
administered wild type and CD44-defficient mice intratracheally with bleomycin, which 
is used to induce a lung injury that is characterized by inflammation of alveolar 
interstitium and the accumulation of ECM. The group found that CD44 and HMWHA 
contribute to the resolution of inflammation [46]. Additionally, Bollyky et al. have shown 
that HMWHA, not LMWHA, has the ability to induce the suppressive effects of 
regulatory T-cells (r-Tc). The group proposed that the state of HA in the ECM provides a 
signal to r-Tc and T-cells (Tc) and provides a link between the innate and adaptive 
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immunities. Whereas both HMWHA and LMWHA were able to bind r-Tc, only 
HMWHA was able to induce the suppressive effect on these cells, which is to suppress 
the proliferation of Tc. Interestingly, the group has shown that HMWHA can by itself 
suppress the proliferation of Tc, directly [47].  
1.2.6.2 Role of LMWHA in inflammation 
Molecules that can mediate and perpetuate an immune response in the absence of 
an infectious agent are known as Damage Associated Molecular Patterns, or DAMPs, as 
opposed to PAMPs (Pathogen Associated Molecular Patterns), which initiate a pathogen-
related inflammatory response. Fragmentation of intact HMWHA through the activity of 
the HYAL enzymes, particularly HYAL2, or by ROS species, results in the formation of 
LMWHA, or HA fragments, which function as DAMPs. Many reports have shown that 
fragmented HA is a pro-inflammatory molecule and is capable of signaling cellular 
responses through specific receptors, including CD44 and toll-like receptors (TLR) 4 and 
8 [37,44]. 
 Many reports have shown that HA fragments can activate immunocompetent 
cells, including dendritic cells and macrophages. Termeer et al. have shown that HA 
fragments induce dendritic cell maturtion through a TLR4-dependent mechanism. They 
showed that dendretic cells expressing a mutant form of TLR4 were not activated by HA 
fragments, whereas dendretic cells lacking TLR2 were. Additionally, blocking TLR4 
abolished the production of HA-fragment-induced TNF-α. The HA/TLR4-dependent 
dendretic cell maturation required the activity of p38-MAPK and P42/44-MAPK and 
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nuclear translocation of NF-κB, consistent with the signaling cascade involving TLR4 
[48].  
In monocytes, HA fragments were able to stimulate the production of interleukin-
6 (IL-6) and monocyte chemoattractant protein-1 (MCP1) through both TLR4- and 
CD44-dependent mechanisms. Yamawaki et al. have shown that peripheral blood 
mononuclear cells (PBMCs) specifically expressed TLR4 and CD44, among other HA 
receptors. LMWHA, but not HMWHA, stimulated the production of IL-6 and MCP-1 
production in PBMCs. When cells were incubated with antibody against CD44, the 
production of IL-6 and MCP-1 in LMWHA-stimulated PBMC was significantly reduced. 
Additionally, the production of IL-6 by cells lacking TLR4 and CD44 was reduced [49].  
Recent studies have shown that HA fragments can also induce innate host defense 
responses at the intestinal epithelium. Hill et al. have shown that HA fragments with a 
specific size of 35-kDa (HA-35), but not larger, can promote the expression of an innate 
antimicrobial peptide known as human β-defensin 2 (HβD2) in intestinal epithelial cells. 
The group treated colonic epithelial cells with different HA sizes and found that only the 
35-kDa HA preparation induced the expression of HβD2 in these cells. Additionally, the 
group tested the expression of HβD2 in vivo in response to HA-35 treatment. They found 
that oral administration of HA-35 induced the expression of the mouse ortholog of HβD2 
in the colonic epithelium of both wild-type and CD44-deficient mice but not in TLR4-
deficient mice, suggesting that the induction of HA-35-mediated innate host defense 
depends upon TLR4, but not CD44 [50]. 
1.2.6.3. Pathological HA cables 
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A special type of pathological HA that also exists in the body, mostly under 
inflammatory conditions, is referred to as HA cables. HA cables are large HA structures 
decorated with proteins, including the heavy chains of IαI, tumor TNFα-stimulated gene 
6 (TSG6) and versican. The major feature that functionally distinguishes HA cables from 
other non-pathological HA structures is their ability to bind leukocytes. These leukocyte 
adhesive HA matrices have been reported in many inflammatory diseases, including 
intestinal tissues of IBD patients, lung tissues of asthmatic patients, lung tissues from 
idiopathic pulmonary hypertension patients, and synovial fluid of patients with arthritic 
disease [51,52]. Additionally, HA-cable formation was accomplished in vitro by inducing 
endoplasmic reticulum stress or by virus infection in intestinal and airway smooth muscle 
cells [53,54]. Figure 1.3 shows intestinal mucosal smooth muscle cells before (1.3A) and 
after (1.3B) they were stimulated with polyI:C, which is a double stranded RNA that 
mimics a virus infection. Whereas most HA in non-stimulated cells appears to be 
intracellular, HA in polyI:C-stimulated cells appears to be forming cable-like structures 
that span the surfaces of multiple cells. 
 HA cables have been shown to be associated with heavy chains of IαI [51]. IαI is 
a plasma proteoglycan that is produced in the liver. It consists of a single chondroitin 
sulfate chain and three proteins covalently linked to the chondroitin sulfate chain: heavy 
chain 1, heavy chain 2, and bikunin, which exerts the trypsin inhibition function of IαI 
[55]. During inflammation, IαI can leak from serum into the extravascular spaces as a 
result of increased vascular permeability. The exposure of IαI to the extracellular matrix 
allows it to function as a heavy chain donor to HA. TSG-6, an enzyme and a HA binding 
protein, facilitates the transfer of heavy chains 1 and 2 from IαI to HA to form the 
22 
 
leukocyte-adhesive HA structure. Importantly, TSG-6 expression increases in the 
inflamed tissues, which emphasizes the role HA cables play in inflammation [56]. 
A  
B  
Figure 1.3: HA cables on the surface of poly:I:C-stimulated mucosal intestinal 
smooth muscle cells (M-SMCs). (A) M-SMCs before they were stimulated with 
polyI:C, which is a double stranded RNA that mimics a virus infection. Most HA (green) 
appears to be intracellular. (B) M-SMCs after they were stimulated with polyI:C. HA 
(green) appears to be forming cable-like structures that span the surfaces of multiple 
cells. green = HA, blue = M-SMC nuclei. 
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1.2.6.4. HA cables in intestinal inflammation 
 In 1999, de la Motte et al. showed for the first time that mononuclear leukocytes 
bind specifically to HA on the surface of colonic mucosal smooth muscle cells (M-
SMCs) that were infected with a virus. The group wanted to test the response of cultured 
M-SMCs to virus infection because IBD correlates with virus infections-related flares 
and with increased intestinal mucosal leukocytes. They found that adhesion of leukocytes 
to M-SMCs infected with syncytial virus, measles virus, or polyI:C increased 
significantly compared to non-infected cells.  Interestingly, not only did stimulated M-
SMCs produce more cell-surface HA, but also treatment of these cells with hyaluronidase 
significantly reduced leukocyte adhesion. Additionally, blocking CD44 on leukocyte 
surfaces decreased adhesion to polyI:C-treated M-SMCs. Collectively, the data showed 
that mononuclear leukocytes bind specifically to HA of inflamed cells via CD44 [53]. 
 In a follow-up study [51], the same group showed that treating M-SMCs with 
polyI:C caused HA to form coat-like structures within 3 hours of treatment, which turned 
into long cable structures spanning multiple cells within 17 hours of treatment. 
Importantly, these cable structures were shown to be the principle mediator of leukocyte 
adhesion. Additionally, they showed that IαI is a major component of both the coat-like 
and cable structures and that culturing cells in the presence of an antibody against IαI 
prevented cable formation and, consequently, leukocyte adhesion. The group also showed 
for the first time that inflamed intestinal tissues from patients with IBD have elevated HA 
expression, and that the elevated HA is associated with IαI [51]. 
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 It was still unclear whether the accumulation of HA precedes and promotes 
intestinal inflammation, or it is the result of inflammation. To answer this critical 
question, Kessler et al. used a mouse colitis model and investigated changes in the 
deposition of HA in the intestine and how these changes associated with the changing 
pathological architecture of intestinal tissues over time (figure 1.4). Within 3-7 days of 
oral administration of dextran sulfate sodium (DSS), a heparin-like polysaccharide that 
induces intestinal inflammation, colon HA deposition changed significantly in the 
intestines of the mice. In fact, HA deposition into colonic blood vessels was detected 
before any detected inflammatory infiltrate. Importantly, the group reported that HA 
deposition occurs also in the blood vessels of IBD patients’ colons and that, in vitro, 
human intestinal endothelial cells can form HA cables that are leukocyte adhesive in 
response to TNF-α, a proinflammatory cytokine. Their data provided evidence that the 
deposition of HA is an early event in inflamed intestinal tissue and that it precedes and 
maybe promotes the infiltration of leukocytes [43].  
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Figure 1.4: Detection of HA structures within the blood vessels of an inflamed colon 
of a mouse and a human IBD patient. (A) Mucosal blood vessels in a section of distal 
colon from a mouse treated with DSS have HA (green) within the vessel lumen. (B) 
Colon sections from a Crohn’s disease patient show abundant HA staining (green) 
throughout the mucosa and submucosa. (C) A blood vessel reveals HA structures within 
the intestinal blood vessels, in proximity to leukocytes (red). Nuclei are blue [43]. 
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1.3. Inflammatory Bowel Disease 
Inflammatory Bowel disease (IBD) is a group of chronic inflammatory conditions 
of the intestines. Over 1.5 million people are affected with IBD in the United States and 
the incidence of the disease is increasing around the world. Although IBD can occur at 
any age, the peak onset for the disease occurs in people 15-30-year old. People who 
suffer from IBD put up with a lifelong of medical attention and persistent symptoms, 
including vomiting, diarrhea and rectal bleeding. While the etiology of IBD is not 
completely known, genetic, immunologic, and environmental factors appear to contribute 
to the disease. IBD is also widely associated with a westernized lifestyle [57].  
IBD consists of two main types: Crohn’s disease and ulcerative colitis, among 
other less common inflammatory diseases. Whereas ulcerative colitis is characterized by 
lesions in the large intestine and the rectum as well as inflammatory lesions restricted to 
the bowel mucosa, Crohn’s disease can affect any part of the gastrointestinal tract from 
the mouth to the anus and the inflammation may extend to the bowel wall. In IBD, 
chronic inflammation of the intestine leads to damaged epithelium, which results in a loss 
of its function; instead, a fibrotic non-functional tissue forms in place of the inflamed 
mucosa, which leads to abdominal pain, malnutrition, and poorly controlled bowel. In 
many cases, IBD patients require surgery when they end up with a malfunctioning 
intestine.  None of the currently applied treatments for IBD cure the primary pathological 
processes that lead to the disease; instead, they reduce symptoms [58]. 
1.4. Platelets 
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Platelets are small (about 2 µm in diameter), anucleate, circulating cells that are 
derived from megakaryocytic precursors in the bone marrow. They were first described 
in 1862 as novel blood elements that have roles in haemorrhage and thrombosis. The 
principle physiological functions of platelets are to recognize any damage or injury that 
occurs in the endothelium of blood vessels, act to “seal off” the damage, and prevent 
bleeding by accumulating at the site of the vessel injury and initiating the clotting of the 
blood. Upon vascular damage, platelets get activated after they bind to the collagen or to 
other exposed ECM proteins, which promotes the release of molecules that signal the 
recruitment, and activation, of more platelets [59].   
 The precursors of platelets, the megakaryocytes, are large cells that reside in the 
bone marrow. Each megakaryocyte can release thousands of platelets. First, a 
megakaryocyte undergoes a dramatic rearrangement of its cytoplasm to produce 
elongated and highly branched structures known as proplatelets. Proplatelets extend into 
the blood vessels where they undergo further fragmentation into platelets [60]. 
Circulating, resting platelets have a discoid oval shape and typically a smooth surface. 
However, upon activation, platelets change shape into spheres with spiny looking 
pseudopods (figure 1.5). Importantly, activated platelets release numerous adhesive and 
clotting proteins from their granular stores to the surrounding environment. These 
molecules can be soluble, associated with the platelet surface, or packaged in 
microparticles [61]. For example, P-selectin is an adhesion molecule that is stored inside 
α-granules of resting platelets. However, the protein translocates to platelet surface upon 
activation to exert its adhesion function. 
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 Platelets have three main storage compartments: α-granules, dense granules and 
lysosomes, in addition to their mitochondira and dense tubular system. The most 
abundant storage compartments are α-granules. Their protein contents include 
coagulation factors, adhesive proteins, and inflammatory and angiogenic mediators. 
Interestingly, studies have shown that functional coclustering of proteins within different 
α-granules is possible. For examples, Italiano et al. have identified two classes of α-
granule: one that contains anti-angiogenic factors and another that contains pro-
angiogenic factors [62]. Dense granules, on the other hand, are present in a fewer number 
in platelets and are the principle storage compartments of small molecules such as 
serotonin, ADP, and calcium, which is necessary in the coagulation cascade [63].  
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Figure 1.5: Transmission electron microscopy images of resting and activated 
platelets. Non-activated platelets have a discoid shape with smooth surface, whereas 
activated platelets have more spherical shape and arm-like structures, or pseudopods. The 
figure also shows the granules inside platelets.  
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1.4.1. Platelet role in inflammation 
 Beyond their major role as cellular mediators of thrombosis and hemostasis, 
accumulating evidence suggest that platelets play an important role as immune cells that 
can initiate many inflammatory processes. With more than a trillion platelets circulating 
the human body, platelets represent the most numerous cell type with an immune 
function. Platelets have been linked to the pathogenesis of several inflammatory diseases, 
including rheumatoid arthritis, atherosclerosis, malaria infection, and transplant rejection. 
Depending on the situation, platelets can either have a protective immune effect or a pro-
inflammatory effect [64].  
 Some of the components of platelet α-granules (e.g. platelet factor 4) have no 
known function in thrombosis, but rather they are known to act as chemokines and 
cytokines with the ability of recruiting immune cells and driving inflammation [65]. 
Components of dense granules can also have immune functions, in addition to their 
thrombotic functions. For example, platelets release their dense granular content of ADP 
and ATP. ADP is known to activate P2Y12 on dendritic cells, resulting in increased 
antigen endocytosis and processing, whereas ATP can signal through T-cell P2X7 
resulting in the differentiation of CD4
+
 T helper cell into a proinflammatory T-helper 17 
cell [66,67]. 
 Studies have also shown that platelets can induce acute phase response (APR), 
which is the earliest response to infection during which the growth of microbes is 
inhibited by specialized proteins and the infection is limited by trapping pathogens within 
local blood clots. Platelets can serve as a major source of innterleukin-1β (IL-1β), which 
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is cytokine that is known to induce APR. Interestingly, IL-1β is not found in resting 
platelets; instead, platelets have IL-1β pre-mRNA and the required machinery to process 
it into mRNA and synthesize and release a functional IL-1β protein upon activation [68]. 
Additionally, it has been shown that platelets get activated postinfection in a mouse 
model of malaria and that platelet IL-1β has a role in inducing APR in these animals [69].  
 Platelets store numerous inflammatory mediators, which can be released upon 
activation. For example, platelet-expressed CD154 can promote leukocyte recruitment to 
sites of inflammation through interaction with endothelial cell-derived CD40. Platelets 
also express a number of the toll-like receptor (TLR) family members, such as TLR4 and 
TLR9. Platelet TLR4, for example, binds bacterial LPS and can present bacterial 
products to neutrophils; whereas TLR9 expressed on activated platelets can mediate 
bacterial DNA sequestration [70].  
1.4.2. Platelets in IBD 
 Abnormalities in platelets have been reported in both types of IBD: Crohn’s 
disease and ulcerative colitis. Perhaps the most notable platelet abnormalites in IBD are 
that platelets circulate the periphery in a highly activated state and the presence of platelet 
aggregates within mucosal microthrombi in the mucosa of the intestines of patients with 
IBD [71,72]. The role platelets may have in the pathogenesis of IBD is unclear. However, 
there is accumulating evidence that platelets have a role as potent pro-inflammatory cells. 
Activated platelets release biological mediators that induce inflammation through 
processes similar to those used by immune cells, which have a known role in the 
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pathogenesis of IBD. Therefore, understanding the roles platelets play in IBD might be 
crucial to the understanding of the pathogenesis of this enigmatic disease. 
 It is established that patients with an active state of IBD have reactive 
thrombocytosis (higher than normal platelet count) and that their platelet count correlates 
well with the severity of the disease. However, the reason behind the increased number of 
circulating platelets in IBD patients is still unclear [73]. Additionally, reports have shown 
that platelets of IBD patients are smaller in size, with mean platelet volume inversely 
proportional to the levels of C-reactive protein, which is an inflammatory marker. Other 
reports have shown also that platelets of IBD patients have increased density due to their 
increased granular content [74].  
 Several studies have reported on the correlation between platelet activation and 
IBD. For example, it has been reported that IBD patients’ platelets undergo spontaneous 
aggregation in vitro in comparison to control platelets. Additionally, platelet aggregates 
are detected in vivo in patients with IBD. Other reports have shown that IBD platelets are 
more sensitive to in vitro activation by an agonist compared to controls. Importantly, the 
activation state of platelets of IBD patients in peripheral circulation is elevated, indicated 
by the increased expression of platelet activation markers such as P-selectin. Moreover, 
increased levels of some platelet activation-related proteins (e.g. platelet factor 4) have 
been reported in the circulation of IBD patients, suggesting the increased activation state 
of platelets in IBD patients [75,76]. 
1.4.3. Platelet HYAL2 
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Many reports have shown that the degradation of HA can result in the generation 
of small sized HA fragments capable of inducing angiogenic and inflammatory 
responses. In 2009, de la Motte et al. reported that platelets and their megakaryocytic 
precursors contain mRNA and protein of HYAL2, one of the two somatically active 
hyaluronidases commonly found in the human body, without evidence of HYAL1. 
Additionally, they showed that platelets can cleave HA cables from the surfaces of 
activated human intestinal mucosal endothelial cells into fragments capable of 
stimulating monocytes to produce pro-inflammatory mediators, including IL-6 and IL-8. 
Their data provided evidence that platelets, beyond their classic role in hemostasis, 
contribute to the binding and catabolism of HA and can serve as an indirect provider of 
pro-inflammatory cytokines [77]. Therefore, understanding the mechanism by which 
platelets degrade HA is important in order to understand the role platelets play in the 
pathogenesis of inflammatory disease, including IBD.  
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CHAPTER II 
PLATELET HYALURONIDASE-2: AN ENZYME THAT TRANSLOCATES TO 
THE SURFACE UPON ACTIVATION TO FUNCTION IN EXTRACELLULAR 
MATRIX DEGRADATION. 
2.1. ABSTRACT 
Following injury, platelets rapidly interact with the exposed extracellular matrix 
(ECM) of the vessel wall and the surrounding tissues. Hyaluronan (HA) is a major 
glycosaminoglycan component of the ECM and plays a significant role in regulating 
inflammation. We have recently reported that human platelets degrade HA from the 
surfaces of activated endothelial cells into fragments capable of inducing immune 
responses by monocytes. We also showed that human platelets contain the enzyme 
hyaluronidse-2 (HYAL2), one of two major hyaluronidases that digest HA in somatic 
tissues. The deposition of HA increases in the inflamed tissues in several inflammatory 
diseases, including Inflammatory Bowel Disease (IBD). We therefore wanted to define 
the mechanism by which platelets degrade HA in the inflamed tissues. In this study, we 
show that human platelets degrade the pro-inflammatory matrix HA through the activity 
of HYAL2 and that platelet activation causes the immediate translocation of HYAL2 
35 
 
from a distinct population of α-granules to platelet surfaces, where it exerts its catalytic 
activity. Finally, we show evidence that patients with IBD have lower platelet HYAL2 
levels and activity than healthy controls. 
2.2. INTRODUCTION 
Hyaluronan (HA) is a ubiquitous glycosaminoglycan and a major component of 
the extracellular matrix (ECM), and it has a crucial role in regulating inflammation [78]. 
HA is produced by the hyaluronan synthase enzymes (HAS1-3) and is composed of 
repeating disaccharides of D-glucuronic acid and N-acetylglucosamine. Not only can HA 
be synthesized and released, but it can also form a voluminous pericellular coat that 
surrounds cells. The HA coat is either anchored to the cell surface through binding to 
specific cell-surface receptors, such as CD44, or can be retained at the cell surface by 
sustained transmembrane interactions with its synthases [79].
 
 Interestingly, a growing 
body of literature suggests that different sizes of HA exert a wide spectrum of functions 
[38]. In tissues under normal conditions, HA is present in its high molecular weight 
(HMWHA) form (1-10X10
6 
Da). HMWHA functions as a structural, hydrating polymer 
and is also known to be anti-inflammatory [44], protecting from T-cell-mediated liver 
injury and bleomycin-mediated lung injury in mice [45,46]. HMWHA also promotes the 
suppressive effects of regulatory CD4
+
 CD25
+
 T cells [47]. 
Increased HA deposition has also been reported in many inflammatory diseases 
including Inflammatory Bowel Disease (IBD), arthritis, and asthma [42,43]. Importantly, 
degradation of HA results in HA fragments that function as Damage Associated 
Molecular Patterns (DAMPs) [80]. Fragmented HA contributes to wound healing, 
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angiogenesis and inflammation and is capable of signaling cellular responses through 
specific receptors [37]. For example, HA fragments can activate macrophages and 
dendritic cells and can stimulate the transcription of inflammatory genes including TNF-
α, IL-12, and IL-1b [44]. In monocytes, HA fragments were able to stimulate the 
production of IL-6 and monocyte chemoattractant protein-1 through CD44 and toll-like 
receptor 4 (TLR4) [49]. Recent studies have shown that HA fragments can also induce 
innate host defense responses at the intestinal epithelium by promoting the expression of 
human β-defensin-2, a potent antimicrobial peptide [50].  
The accumulation of HA fragments in tissues during injury or under inflammation 
is thought to be largely the result of enzymatic degradation of HA, mainly through 
HYAL1 and HYAL2 in somatic tissues [18,37]. HYAL2 is a GPI-anchored protein that 
digests HA with the cooperation of CD44, the classical HA receptor [81]. Digested HA is 
then either internalized into the lysosome for further digestion, or is released into the 
environment [77,81]. KIAA1199 has recently been identified as a HA binding protein 
and a contributor to HA degradation [30]. HA digestion can also occur by non-enzymatic 
mechanisms, mainly through reactive oxygen species [35].
 
We previously reported that mouse and human platelets and their megakaryocytic 
precursors express both HYAL2 mRNA and protein with no evidence for HYAL1. We 
also showed that platelets can degrade endothelial pro-inflammatory matrix HA into 
signaling sized HA fragments that stimulate monocytes [77]. Platelets can act as 
inflammatory cells, beyond their main role in thrombus formation [59]. They store 
numerous inflammatory mediators in their granules, which can be released upon 
activation [64]. For example, CD154 on the surface of activated platelets can promote 
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leukocyte recruitment to sites of inflammation [82]. Platelets also express a number of the 
TLR family members. Platelet TLR4, for instance, can bind bacterial LPS; whereas 
TLR9 expressed on activated platelets can mediate bacterial DNA sequestration [70,83].
 
In this report, we define a novel mechanism by which platelets modify the ECM. 
We demonstrate that after activation, platelets degrade the pro-inflammatory matrix using 
HYAL2. This activation-dependent mechanism results in the immediate translocation of 
HYAL2 from α-granules to platelet surfaces, where it exerts its catalytic activity. 
Furthermore, we show that platelets of patients with IBD have lower HYAL2 protein 
content and hyaluronidase activity than control platelets, which might explain the 
accumulation of the leukocyte-adhesive HA observed in IBD tissues.
 
2.3. MATERIALS AND METHODS 
2.3.1. Materials 
Fetal Bovine Serum (FBS) was from GIBCO Life Technologies, Carlsbad, CA. 
100 µM cell screens were from EMD Millipore, Germany. Acid-Citrate-Dextrose (ACD) 
was from BD Biosciences, Franklin Lakes, NJ. Streptomyces hyaluronidase, Benzonase® 
and prostaglandin E1 were from Sigma Aldrich, St. Louis, MO. Thrombin Receptor 
Activating Peptide (TRAP-6) was from Tocris Bioscience, UK. Anion exchange spin 
columns were from Thermo Scientific, Waltham, MA. Hyaluronan ELISA-like assay was 
from Echelon Biosciences, Salt Lake City, UT. Select-HA™ was from Lifecore 
Biomedical, LLC, Chaska, MN. Vectasheild Mounting Medium with DAPI was from 
Vector Labs, Burlingame, CA. 
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2.3.2. Cell Isolation and Culture 
Human intestinal mucosal smooth muscle cells (M-SMCs) were isolated from 
colon surgical specimens (obtained from the Department of Surgical Pathology at the 
Cleveland Clinic) and cultured as previously described [51]. Briefly, 3-centimeter strips 
of the colon mucosal layer were incubated in Hanks’ BSS (HBSS) containing 0.15% 
dithiothreitol (w/v) for 30 min, washed in HBSS containing 1 mM EDTA for 3 h, and 
finally washed in HBSS for 2 h. The strips were cut into small pieces and then digested 
with 0.1 mg/mL collagenase and 0.1 mg/mL DNase for 18 h. The liberated cells were 
filtered through 100 µM cell screens, washed, suspended in DMEM/F12 media 
containing 10% FBS and cultured on tissue culture plastic incubated at 37°C in a 5%CO2  
humidified environment. 
2.3.3. Platelet Isolation 
Blood was collected by sterile venipuncture (without use of a tourniquet) directly 
into tubes containing Acid-Citrate-Dextrose (ACD) from consented healthy donors as 
approved by the Cleveland Clinic Institutional Review Board.  The citrated blood was 
centrifuged for 20 min at 200g without applying break. The Platelet-Rich Plasma (PRP) 
layer was then collected, prostaglandin E1 was added to a final concentration of 35 
ng/ml, and the PRP centrifuged for 20 min at 600g. The resulting platelet pellet was then 
washed twice with HBSS containing 35 ng/mL PGE1. 
2.3.4 Cell co-culture assay for platelet hyaluronidase activity and fragment 
generation 
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Confluent human intestinal mucosal smooth muscle cells (M-SMCs) isolated 
from colon surgical specimens (obtained from the Department of Surgical Pathology at 
the Cleveland Clinic) were grown in 24-well cell culture plates and treated without or 
with 50 µg/mL polyI:C for 18 h.  Culture media were replaced with RPMI media 
containing 1% FBS alone or containing freshly isolated resting platelets or Thrombin 
Receptor Activating Peptide (TRAP-6)-activated platelets (25 µM for 1 min at RT). Co-
cultures were incubated for 2 h at 37°C. In some experiments, platelets were pre-
incubated with blocking antibody against HYAL2 (1, 12, and 25 µg/ml) (Thermo) or 
control IgG (25 µg/ml). Culture media were collected and centrifuged to remove 
platelets. Total HA released into the media was measured using a competitive ELISA-
like assay (Echelon) according to the manufacturer’s protocol. Unbound platelets, 
obtained by collection and centrifugation of culture media, and SMC-bound platelets, 
obtained by scraping SMCs from wells, were analyzed by flow cytometry for their 
surface P-selectin and HYAL2 expression.  
2.3.5. Platelet microparticle isolation 
Platelet microparticles were isolated as previously described [84]. Briefly, freshly 
isolated platelets were incubated without or with 15 μM TRAP for 10 minutes at 37°C 
and centrifuged at 750g for 20 minutes (platelet fraction). The supernatant platelet 
releasate was placed on ice and centrifuged at 10,000g for 30 minutes at 4°C to obtain the 
microparticles fraction. Platelet fraction (750g pellet), microparticles’ fraction (104 g 
pellet), and platelet releasate (10
4
 g supernatant) were analyzed by western blotting for 
the presence of HYAL2. 
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2.3.6. Immunohistochemical staining of platelets 
Resting or TRAP-activated freshly isolated platelets were fixed in 3.5% 
paraformaldehyde for 30 min at RT. Fixed platelets were spun onto a poly-l-lysine coated 
8-well chamber slide at 250g for 10 min. Where indicated, permeablization of platelets 
was done by adding cold methanol for 5 min. Fixed specimens were incubated with 
blocking buffer (2% FBS in HBSS) for 1 h. Non-permeablized platelets were incubated 
with antibodies against HYAL2 and P-selectin. Permeablized specimens were incubated 
with an antibody against HYAL2 and an antibody against one of the following: CD42b, 
LAMP2, PDI, KDEL, LAMP-1, NEU1, P-selectin, vWF, and fibrinogen. A permeablized 
specimen was incubated with antibodies against P-selectin and vWF as a positive control 
for co-localization. After washing, specimens were incubated with the appropriate Alexa 
Fluor® secondary antibody for 45 min at RT, washed again, and Vectasheild Mounting 
Medium with DAPI was added. Images were obtained using either Leica TCS SP5 II 
Confocal/Multi-Photon high speed upright microscope or Leica upright microscope 
DM5500 B (Leica, Germany). Pearson’s correlation coefficients were obtained by 
analyzing individual images of the Z-stack using Image-Pro Plus software (Rockville, 
MD). See table 2.1 for a complete list of antibodies used and concentrations. 
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Table 2.1: List of antibodies used for the immunohistochemical staining of platelets. 
Antigen Host species Company Concentration   
used 
Secondary antibody 
used* 
HYAL2 Rabbit 
polyclonal 
Thermo Scientific 
(Waltham, MA) 
1:50 Alexa Fluor® 488 
Donkey Anti-Rabbit 
IgG (1:1000) 
CD42b Goat polyclonal Santa Cruz Biotech 
(Santa Cruz, CA) 
1:100 Alexa Fluor® 568 
Donkey Anti-Goat IgG 
(1:1000) 
LAMP1 Mouse 
monoclonal 
Ebioscience (San 
Diego, CA) 
1:50 Alexa Fluor® 568 Goat 
Anti-Mouse IgG 
(1:1000) 
LAMP2 Mouse 
monoclonal 
Ebioscience (San 
Diego, CA) 
1:50 Alexa Fluor® 568 Goat 
Anti-Mouse IgG 
(1:1000) 
PDI Mouse 
monoclonal 
Abcam 
(Cambridge, 
England) 
1:100 Alexa Fluor® 568 Goat 
Anti-Mouse IgG 
(1:1000) 
KDEL Mouse 
monoclonal 
Abcam 
(Cambridge, 
England) 
1:100 Alexa Fluor® 568 Goat 
Anti-Mouse IgG 
(1:1000) 
vWF Goat polyclonal Santa Cruz Biotech 
(Santa Cruz, CA) 
1:25 Alexa Fluor® 568 
Donkey Anti-Goat IgG 
(1:1000) 
P-selectin Goat polyclonal Santa Cruz Biotech 
(Santa Cruz, CA) 
1:50 Alexa Fluor® 568 
Donkey Anti-Goat IgG 
(1:1000) 
Fibrinogen Mouse 
monoclonal 
Cedarlane Labs 
(Burlington, ON) 
1:100 Alexa Fluor® 568 Goat 
Anti-Mouse IgG 
(1:1000) 
NEU1 Mouse 
monoclonal 
Santa Cruz 
Biotech (Santa 
Cruz, CA) 
1:50 Alexa Fluor® 568 
Goat Anti-Mouse IgG 
(1:1000) 
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2.3.7 Flow Cytometry 
Freshly isolated resting or TRAP-activated (25 µM for 1 min at RT) platelets 
were fixed in 1% paraformaldehyde for 2 h at RT. Fixed platelets were washed then 
incubated for 1 h at RT in flow cytometry buffer (0.1% BSA, 0.05% sodium azide in 
PBS) with anti-HYAL2 (Thermo) (1:100), Allophycoerythrin (APC)-conjugated anti-P-
selectin (Ebioscience) (1:1000), and anti-CD16/CD32 (to block the Fc receptors, 1:100). 
Platelets were washed then incubated with Alexa Fluor® 568 Goat Anti-Rabbit IgG for 
30 min at RT. 30,000 events/sample were acquired on a BD Bioscience LSR II (BD 
Biosciences) flow cytometer. Data were analyzed using FlowJo (Tree Star, Ashaland, 
OR). 
2.3.8 Subcellular fractionation of platelets using differential centrifugation 
Freshly isolated platelets were sonicated and subcellular fractionation was 
achieved as previously described [85]. Briefly, platelet lysates were centrifuged at 1,000g 
to remove unlysed platelets, and then at 19,000g to obtain pellets that contain granules 
and lysosomes. Supernatants were ultracentrifuged at 100,000g to obtain pellets 
containing membranes and supernatants containing cytosol. Membranes were further 
fractionated into dense tubular system (DTS) and plasma membranes by layering on 40% 
sucrose and ultracentrifuging at 100,000g. Fractions containing equal total proteins were 
analyzed by immunoblotting for the presence of HYAL2 and CD42b. 
2.3.9 Immuno-electron microscopy 
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Freshly isolated resting or TRAP-activated platelets were fixed with 3.5% 
paraformaldehyde and 0.09% gluteraldehyde for 30 min at RT and then centrifuged. 
Platelet pellets were washed with PBS, dehydrated with ethanol (30%-100%), embedded 
with LR White medium, and polymerized at 50°C for 48 h. Ultrathin sections cut with a 
diamond knife (87 nm) were mounted on formvar-coated nickel grids. Grids were 
rehydrated with PBS, blocked with 1% BSA for 30 min, and incubated with rabbit anti-
HYAL2 antibody (Abcam) (1:50) for 18 h. Grids were washed and incubated with 10 nm 
gold-conjugated goat anti-rabbit IgG (Redding, CA) (1:10) for 1 h. Grids were washed 
again, fixed with 1% gluteraldehyde, and washed with distilled water. Grids were then 
stained with uranyl acetate and lead citrate, dried and examined with a FEI Tecnai G2 
Spirit BioTWIN Transmission Electron Microscope (FEI Company, Hillsboro, OR) at 60 
kV. 
2.3.10 Statistical analysis 
All statistics were performed using the Student t test. Data is presented as mean ± 
standard error unless otherwise mentioned. Patient data were presented as scatter plot 
showing mean ± standard error and as box-and-whiskers plot showing median and 10-90 
percentiles. P-values below 0.05 were considered statistically significant. 
2.3.11. Immunofluorescence histochemical staining of M-SMCs 
M-SMCs from the co-culture assay grown on coverslips were washed and then fixed in 
cold methanol for 5 min. Coverslips were incubated in blocking buffer (2% FBS in 
HBSS) for 1 h at RT, and then in blocking buffer containing 5 µg/mL biotinylated HA 
binding protein (EMD Millipore, Germany) and anti-CD42b (1:100) for 18 h at 4°C. 
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Coverslips were then washed and incubated with blocking buffer containing detection 
reagents Alexa Fluor® 488 streptavidin (1:500) and Alexa Fluor® 568 Donkey Anti-
Goat IgG (1:1000) (Life Technologies, Carlsbad, CA) for 45 min at RT. The stained 
coverslips were washed and mounted onto slides. Images were obtained using Leica TCS 
SP5 II Confocal or Leica upright microscope DM5500 B (Leica, Germany). 
2.3.12 HA isolation and sizing 
HA was purified from stimulated M-SMCs before and after they were co-
incubated with platelets. M-SMCs were incubated with 0.5 mg/ml proteinase-K in PBS 
for 18 h at 60°C, then with benzonase® (50 U/ml) for 1 h at 37°C. Samples were then 
concentrated using speedvac and dialyzed against 0.1 M NaCl. Samples were applied to 
anion exchange spin columns (Thermo) and centrifuged for 5 min. Columns were washed 
with 0.1 M and 0.4 M NaCl before HA was eluted with 0.8 M NaCl. Eluted samples 
containing HA were dialyzed against water, concentrated, and analyzed using 0.5% 
agrose sizing gel as described previously [86]. Stained bands in the gel were confirmed to 
be HA by demonstrating sensitivity to Streptomyces hyaluronidase (2 U/ml for 1 h at 
37°C). 
2.3.13 Hyaluronidase assay using immobilized purified HA 
Freshly isolated resting, or TRAP-activated, or lysed platelets resuspended in 
neutral or acidic RPMI medium were added to a 96-well plate coated with HA (Echelon) 
(3X10
8
 platelets/well). The plate was incubated at 37°C for 18 h and then washed. 
Residual HA was detected colorimetrically using HA detection system provided by the 
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manufacturer. Streptomyces hyaluronidase (2 U/ml) was used as a positive control and 
for defining maximum activity. 
2.3.14 Hyaluronidase assay using purified HA in solution 
Platelets were incubated at 37°C for 18 hours in RPMI medium containing 1000 
kDa Select-HA™ (5 µg/ml), an enzymatically synthesized commercial HA with high size 
control. Samples from the incubation were analyzed for HA by 0.5% agarose gel 
electrophoresis as described previously
28
 (0.5 µg of HA/lane).  
2.3.15 Subcellular fractionation of platelets using sucrose density gradient 
This was achieved as previously described [87]. Briefly, freshly isolated platelets 
were sonicated and applied on top of a linear 30-60% sucrose gradient followed by 
ultracentrifugation for 100,000g for 90 min. Nine fractions were collected by pipetting 
from the top, and equal volumes of fractions were analyzed by immunoblotting for the 
presence of HYAL2, P-selectin, von Willbrand factor (vWF), CD42b, and LAMP-1.  
2.4. RESULTS 
2.4.1 Platelets degrade pro-inflammatory matrix HA 
de la Motte et al. have recently demonstrated that platelets can digest HA from 
surfaces of activated endothelium, which produces fragmented HA capable of promoting 
cellular responses [77]. In order to investigate the mechanism by which platelets cleave 
matrix HA, we adopted a cell co-culture assay. Cultured human intestinal mucosal 
smooth muscle cells (M-SMCs) isolated from surgical specimens were treated with 
polyI:C, a double stranded RNA used to mimic a virus infection, to stimulate production 
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of pro-inflammatory, leukocyte-adhesive HA. Freshly isolated human platelets were co-
incubated with polyI:C stimulated M-SMCs for two hours at 37°C. Cell-associated HA 
was then purified and analyzed by agarose gel electrophoresis. The highly polydisperse 
cell-associated HA in the size range of 0.5-2 x10
6
 Da was detected on the stimulated cells 
(figure 2.1A lane 1). However, HMWHA was not detected on cells co-incubated with 
platelets (figure 2.1A lane 2) indicating that platelets cleared most of the pro-
inflammatory matrix HA on the M-SMC surface. Replicate samples were subjected to 
Streptomyces hyaluronidase, an enzyme that specifically degrades HA, to confirm that 
the stained bands were HA (figure 2.1A lane 3&4). In order to test whether the HA 
cleaved by platelets is released into the culture medium, we measured HA in the culture 
fluid by an ELISA-like assay. As expected, polyI:C treated cells released significantly 
higher amounts of HA than non-treated cells (P<0.001). However, when polyI:C treated 
cells were incubated with platelets, the amount of HA released was significantly 
increased (P<0.001) (Figure 2.1B). The effect that platelets have on HA in the 
extracellular matrix is striking when observed by histochemical staining. Upon polyI:C 
treatment, M-SMCs produced large amounts of leukocyte-adhesisve HA structures or 
“HA cables” (figure 2.1C-green). Following co-incubation with platelets, HA cables were 
completely removed from the surfaces of M-SMC, confirming the role of platelets in 
clearing pro-inflammatory HA. To assess the activation state of platelets in culture and 
whether culture conditions (e.g. serum and SMC surface molecules) contribute to platelet 
activation, we analyzed their surface P-selectin by flow cytometry. We found that 
platelets that were bound to SMCs demonstrated significantly higher surface expression 
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of P-selectin compared to unbound platelets. Importantly, bound platelets also showed a 
significant increase in surface HYAL2 compared to unbound platelet (figure 2.1D). 
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Figure 2.1: Platelets digest HA in the inflammatory matrix. PolyI:C stimulated human 
M-SMCs were co-incubated with freshly isolated human platelets for 2 hours at 37°. (A) 
Agarose gel electrophoretic analysis of HA purified from polyI:C stimulated M-SMCs 
before (lane 1) and after (lane 2) co-incubation with platelets. Polydisperse HA with a 
size range of 0.5-2 X10
6
 Da associated with M-SMCs was no longer detected after co-
incubation with platelets. Replicate samples were treated with Streptomyces 
hyaluronidase (HAase), an enzyme that specifically digests HA, to confirm that the 
stained bands were HA (lanes 3&4). HA ladder units: 10
6
 Dalton. 
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Figure 2.1 (cont.): Platelets digest HA in the inflammatory matrix. PolyI:C stimulated 
human M-SMCs were co-incubated with freshly isolated human platelets for 2 hours at 
37°. (B) ELISA-like assay measurement of HA released into the media by M-SMCs. Co-
incubation of M-SMCs with platelets results in a significant increase of HA in culture 
media. (Data represent mean ± SE of 10 separate experiments, ***P<.001. 
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Figure 2.1 (cont.): Platelets digest HA in the inflammatory matrix. PolyI:C stimulated 
human M-SMCs were co-incubated with freshly isolated human platelets for 2 hours at 
37°. (C) Histochemical staining of M-SMC-associated HA (green). M-SMCs were fixed 
in cold methanol, and HA was detected with biotinylated HA binding protein and Alexa 
Fluor® 488-conjugated streptavidin. M-SMCs responded to polyI:C treatment by 
producing high amounts of HA. The co-incubation of platelets with polyI:C stimulated 
M-SMCs caused the removal of the M-SMC surface-associated HA. Image details for 
figure 1C: Microscope: Leica upright microscope DM5500 B (Leica, Germany). 
Objective: HC PLAN APO 20X/0.7NA dry. Camera: QImaging Retiga cooled CCD 
camera. Acquisition software: QCapture Suite Software (QImaging, Surrey, BC). Scale 
bar: 100 µm. 
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Figure 2.1 (cont.): Platelets digest HA in the inflammatory matrix. PolyI:C stimulated 
human M-SMCs were co-incubated with freshly isolated human platelets for 2 hours at 
37°. (D) Fold-increase in surface P-selectin and HYAL2 MFI of SMC-bound platelets in 
comparison to unbound platelets following culture as measured by flow cytometry. SMC-
bound platelets demonstrated significantly higher surface P-selectin and HYAL2 
compared to unbound platelets after culture. 
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2.4.2 Degradation of matrix HA by platelets is HYAL2 dependent 
The two somatically active HA degrading enzymes in humans are HYAL1 and 
HYAL2 [27]. We showed previously that platelets contain only HYAL2 protein and 
mRNA, with no evidence of HYAL1 [77]. Additionally, we observed in the previous 
experiments that HYAL2 increases on the surface of platelets bound to SMCs in culture. 
Therefore, we hypothesized that pro-inflammatory HA clearance by platelets is mediated 
by platelet HYAL2. To test this hypothesis, we incubated platelets with different 
concentrations of HYAL2 neutralizing antibodies, or with non-specific control IgG, 
before they were co-incubated with polyI:C-stimulated M-SMCs. We then analyzed HA 
released into the media by the ELISA-like assay. HA concentrations in media collected 
from M-SMCs that were incubated with HYAL2 antibody-treated platelets were 
significantly lower than media collected from cells incubated with either untreated 
platelets or platelets pre-incubated with IgG (Figure 2.2A) (P<0.05, N=3). We confirmed 
that the effect of the blocking antibody is specific to platelet HYAL2, not SMC HYAL2, 
by centrifuging the HYAL2 antibody-treated platelets to remove excess antibody before 
they were added to the culture (data not shown). To further confirm HYAL2 antibody 
blockade, we performed histochemical staining of HA on polyI:C stimulated M-SMC 
(green) co-incubated with platelets (red for CD42b) in the absence or presence of 
HYAL2 antibody (Figure 2.2B).  HA cables on the surfaces of M-SMCs that were co-
incubated with HYAL2 antibody-treated platelets remained intact whereas HA on M-
SMCs co-incubated with untreated platelets was removed, consistent with our ELISA-
like data. Interestingly, HYAL2 antibody-treated platelets retained their HA cable 
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binding ability, an observation previously reported when monocytes or platelets were 
incubated with HA cables at 4°C.
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Figure 2.2: Platelets degrade pro-inflammatory matrix HA using HYAL2. PolyI:C 
stimulated human M-SMCs were co-incubated with untreated freshly isolated human 
platelets or with HYAL2 blocking antibody-treated platelets for 2 hours at 37°. (A) 
ELISA-like assay measurement of the amounts of HA released into the media by M-
SMCs. Co-incubation of stimulated M-SMCs with HYAL2 antibody-treated platelets 
resulted in a significant decrease in HA released into media compared to untreated or 
IgG-treated platelets (N=3, *P<.05). The inhibiting effect of the HYAL2 blocking 
antibody was dose dependent. 
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Figure 2.2 (cont.): Platelets degrade pro-inflammatory matrix HA using HYAL2. 
PolyI:C stimulated human M-SMCs were co-incubated with untreated freshly isolated 
human platelets or with HYAL2 blocking antibody-treated platelets for 2 hours at 37°. 
(B) Histochemical staining of M-SMC-associated HA (green) and platelets (red = 
CD42b) in the absence or presence of HYAL2 antibody. Whereas untreated platelets 
degraded HA on stimulated M-SMCs, HYAL2 antibody-treated platelets bound HA 
cables on the surfaces of M-SMCs without degrading them. Image details for figure 2B: 
Microscope: Leica TCS SP5 II Confocal/Multi-Photon high speed upright microscope 
(Leica, Germany). Objective: HCX PL APO 40X/1.25NA oil immersion. Detector: Leica 
HyD™ system. Acquisition software: Leica LAS AF software (Leica, Germany). Scale 
bar: 25 µm. 
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2.4.3 Degradation of purified HA by platelets and platelet lysates only occurs at low 
pH 
HYAL2 is reported to be an acid active enzyme [23]. With the observation that 
platelets degrade matrix HA by HYAL2 under physiological conditions (pH 7.2), we 
tested whether platelets have the ability to degrade purified HA under neutral pH using 
two approaches: 1) can platelets degrade purified HA immobilized to a surface? 2) can 
platelets degrade purified HA in solution? We first used a range of pH conditions. 
Platelets that were incubated with immobilized purified HA at neutral pH displayed no 
HA degrading activity; whereas platelets incubated under acidic conditions (pH 2.5-4.5) 
demonstrated HAase activity. Platelet lysates also had a peak HAase activity at pH 3.5 
with no measurable activity at neutral pH (Figure 2.3A). Surprisingly, platelet lysates 
showed significantly higher HAase activity (60% maximum) than whole platelets (20% 
maximum) (P<0.001, N=3) (figure 2.3B). Maximum activity was achieved by 
Streptomyces hyaluronidase. The data suggest that the majority of the resting platelet 
HYAL2 is not on the surface. To test whether platelets can degrade purified HA in 
solution, platelets were incubated with Select-HA™ (1000 kDa), a commercial 
monodisperse HA prepared through enzymatic synthesis where a high level of size 
control is possible. As observed with immobilized HA, platelets were only able to digest 
purified HA in solution under acidic pH (Figure 2.3C). 
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Figure 2.3: Platelets and platelet lysates can only degrade purified HA under acidic 
pH. (A&B) Platelets and platelet lysates were incubated with purified HA immobilized to 
wells of a 96-well plate for 18 hours at 37°C (3X10
8 
platelets/well). At the end of the 
incubation, platelets and degraded HA were washed away and HAase activity was 
measured by detecting residual HA colorimetrically. Maximum activity (100%) was 
achieved by Streptomyces hyaluronidase. (A) HAase activity of platelets and their lysates 
at different pHs. Platelets and their lysates demonstrated purified HA-degrading activity 
only under acidic pH (optimum pH=3.5) with no detectable activity at neutral pH. 
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Figure 2.3 (cont.): Platelets and platelet lysates can only degrade purified HA under 
acidic pH. (A&B) Platelets and platelet lysates were incubated with purified HA 
immobilized to wells of a 96-well plate for 18 hours at 37°C (3X10
8 
platelets/well). At 
the end of the incubation, platelets and degraded HA were washed away and HAase 
activity was measured by detecting residual HA colorimetrically. Maximum activity was 
achieved by Streptomyces hyaluronidase. (B) Purified HA-degrading activity of platelets 
compared to the activity of their lysates. Platelet lysates have significantly higher purified 
HA-degrading activity than intact platelets. (***P<.001, N=3). 
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Figure 2.3 (cont.): Platelets and platelet lysates can only degrade purified HA under 
acidic pH. (C) Purified HA (Select-HA™, 1000 kDa) in RPMI medium (5 mg/ml) was 
incubated with platelets (300 x 10
6
 plts/ml) for 18 hours at 37°C. Platelets degraded 
purified HA only under acidic pH (pH=3.5), but not under neutral pH.  
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2.4.4 HYAL2 becomes surface-expressed on thrombin receptor-activated platelets. 
The observations that HYAL2 increased on the surface of SMC-bound platelets, 
which was also accompanied by an increase in surface P-selectin expression, and that 
platelet lysates had significantly higher HAase activity than intact platelets suggested that 
platelet activation may have a role in the surface expression of HYAL2. Therefore, we 
analyzed the normal HYAL2 expression parameters in resting and activated platelets. 
First, we examined whether activated platelets package HYAL2 into microparticles. 
Immunoblot analysis revealed that, upon activation, HYAL2 remains associated with 
platelets, and does not associate with microparticles or any platelet releasate, even after 
30 minutes of incubation with TRAP (figures 2.4A & 2.4B).  We then compared HYAL2 
expression in paraformaldehyde fixed, non-permeablized platelets by 
immunohistochemical staining using fluorescence microscopy (Figure 2.4C). Surface 
expression of P-selectin (red) was used as a platelet activation marker. TRAP-activated 
platelets showed significantly higher HYAL2 staining levels than resting platelets. Since 
platelets were not permeablized, the data provided evidence that HYAL2 is targeted to 
platelet surfaces only upon activation. Next we analyzed surface expression of HYAL2 in 
unstimulated and TRAP-stimulated platelets by flow cytometry. To eliminate the 
spontaneously activated platelets in the unstimulated population, we gated on the strictly 
P-selectin negative population in that sample. The P-selectin negative population 
demonstrated no surface HYAL2 expression, whereas the P-selectin positive population 
in the TRAP-stimulated sample showed significant surface HYAL2 expression (figure 
2.4D). We also determined, using flow cytometry analysis, that only 6.8 ± 1.3% (±SE) of 
non-activated (P-selectin negative) platelets in the tested population expressed surface 
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HYAL2 compared to 37.6 ± 6.4% (±SE) of activated platelets (P<0.001, N=9) (Figure 
2.4E). Flow cytometry analysis also showed a 3-fold increase in Mean Fluorescence 
Intensity (MFI) of surface HYAL2 in TRAP-activated platelets compared to non-
activated platelets (P<0.001, N=9) (Figure 2.4F).  
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Figure 2.4: HYAL2 becomes surface expressed upon thrombin receptor-mediated 
platelet activation. (A) Freshly isolated human platelets were treated without or with 
TRAP (15 µM) for 10 minutes before microparticles were isolated. Immunoblot analysis 
showed that, upon activation, HYAL2 was associated with platelets (750 g pellet) and not 
with microparticles (10
4
 g pellet) or platelet releasate (10
4
 sup.). (B) Immunoblot analysis 
showing that HYAL2 remains associated with platelets (750g pellet) and not with 
microparticles or releasate (REL) even after 30 minutes incubation with TRAP. 
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Figure 2.4 (cont.): HYAL2 becomes surface expressed upon thrombin receptor-
mediated platelet activation. (C) Freshly isolated human platelets were treated without 
or with TRAP (25 µM) for 1 minute before they were fixed with 3.5% paraformaldehyde 
for 30 minutes. Fixed platelets were spun down onto poly-l-lysine coated slides and 
stained for P-selectin (red) and HYAL2 (green). Similar to P-selectin, HYAL2 was only 
detected on the surfaces of activated platelets. Image details for figure 4A: Microscope: 
Leica upright microscope DM5500 B (Leica, Germany). Objective: HCX PLAN APO 
63X/1.32NA oil immersion. Camera: QImaging Retiga cooled CCD camera. Acquisition 
software: QCapture Suite Software (QImaging, Surrey, BC). Scale bar: 20 µm. 
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Figure 2.4 (cont.): HYAL2 becomes surface expressed upon thrombin receptor-
mediated platelet activation. (D,E,&F) Freshly isolated platelets were treated without or 
with TRAP (25 µM) for 1 min at RT before they were fixed in 1% paraformaldehyde for 
2 hours at RT. Fixed platelets were stained for HYAL2 and P-selectin and analyzed using 
flow cytometry. (D) Representative histograms of surface P-selectin and HYAL2 staining 
in unstimulated and TRAP-stimulated platelets. The P-selectin negative population in 
unstimulated platelets demonstrated no surface HYAL2 expression, whereas the P-
selectin positive population in the TRAP-stimulated sample showed significant surface 
HYAL2 expression. 
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Figure 2.4 (cont.): HYAL2 becomes surface expressed upon thrombin receptor-
mediated platelet activation. (D,E,&F) Freshly isolated platelets were treated without or 
with TRAP (25 µM) for 1 min at RT before they were fixed in 1% paraformaldehyde for 
2 hours at RT. Fixed platelets were stained for HYAL2 and P-selectin and analyzed using 
flow cytometry. (E) Percentage of surface HYAL2 positive platelets measured by flow 
cytometry. 37.6 ± 6.4% (±SE) of TRAP-activated platelets expressed surface HYAL2 
compared to only 6.8 ± 1.3% (±SE) of non-activated (P-selectin negative) platelets 
(***P<.001, N=9). 
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Figure 2.4 (cont.): HYAL2 becomes surface expressed upon thrombin receptor-
mediated platelet activation. (D,E,&F) Freshly isolated platelets were treated without or 
with TRAP (25 µM) for 1 min at RT before they were fixed in 1% paraformaldehyde for 
2 hours at RT. Fixed platelets were stained for HYAL2 and P-selectin and analyzed using 
flow cytometry. (F) Fold-increase in surface HYAL2 MFI of TRAP-activated platelets in 
comparison to non-activated (P-selectin negative) platelets. Activated platelets 
demonstrated 3-fold increase in surface HYAL2 expression compared to non-activated 
platelets (***P<.001, N=9).  
 
 
67 
 
2.4.5 Platelet HYAL2 is localized to a distinct population of α-granules  
Since HYAL2 appears to be expressed on the platelet surface only upon 
activation, we hypothesized that HYAL2 is stored inside platelet granules in resting 
platelets. To test this, we wanted to determine whether HYAL2 partitions with granules, 
cytosol or membranes [plasma membranes and dense tubular system (DTS)] in resting 
platelets. First, we separated platelet granules (α-granules, dense granules, lysosomes and 
mitochondria) from platelet membranes by differential centrifugation. The platelet 
membrane marker CD42b was detected, as expected, in the plasma membrane fraction 
(Figure 2.5A). HYAL2, however, was detected specifically in the granule fraction. Next, 
to define the granule type in which HYAL2 is stored, sucrose density gradients were used 
to separate platelet subcellular compartments (Figure 2.5B). HYAL2 and P-selectin, an α-
granule marker, were enriched in the same sucrose fraction, suggesting that HYAL2 is 
stored in platelet α-granules. CD42b and LAMP-1 were used as plasma membrane and 
lysosomal markers, respectively.  
Subsequently, we analyzed co-localization of platelet HYAL2 with different 
platelet granule markers using fluorescence microscopy (Figure 2.5C). Consistent with 
the sucrose density gradient data, platelet HYAL2 staining did not co-localize with 
known specific markers of plasma membranes (CD42b), lysosomes (LAMP-1 and 
NEU1), dense granules (LAMP-2), T-granules (PDI), or the DTS (KDEL). Surprisingly, 
platelet HYAL2 also did not co-localize with the known specific markers of α-granules 
(vWF, P-selectin, and fibrinogen). The lack of co-localization between platelet HYAL2 
and the α-granule markers we examined led us to conclude that HYAL2 is stored in a 
different subset of α-granules inside resting platelets. As a positive control, we analyzed 
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the co-localization of vWF and P-selectin, two known α-granule markers, in platelets. As 
expected, vWF and P-selectin showed significant levels of co-localization (Pearson 
correlation coefficient = 0.65). To finally determine that HYAL2 is stored in platelet α-
granules, given the fact that it did not co-localize with known α-granule markers, we 
examined its localization by immuno-electron microscopy. Inside resting platelets, 
HYAL2 was clearly detected within α-granules, which were identified by their distinct 
morphology and number. However, whereas resting platelet surfaces appeared to be 
devoid of any HYAL2 expression, HYAL2 was clearly detected on the surfaces of 
TRAP-activated platelets (Figure 2.5D). Interestingly, HYAL2 appears to exist in clusters 
on platelet surfaces, unlike the previously reported uniform distribution of adhesion 
molecules, such as P-selectin [88]. 
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Figure 2.5: HYAL2 is stored in a distinct subset of α-granules in resting platelets. 
(A) Immmunoblot analysis, for the presence of CD42b and HYAL2, of different platelet 
subcellular fractions obtained by differential centrifugation. HYAL2 was detected 
exclusively in the fraction containing granules, lysosomes and mitochondria (19,000g 
pellet); whereas CD42b was detected in the membranes fraction (100,000g pellet). 
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Figure 2.5 (cont.): HYAL2 is stored in a distinct subset of α-granules in resting 
platelets. (B) Platelets were sonicated and applied on top of a linear sucrose density 
gradient before the gradient was centrifuged at 100,000g for 90 min. Nine fractions were 
collected from top of the gradient. Equal volumes of fractions were analyzed by 
immunoblotting for the presence of CD42b (plasma membrane marker), LAMP-1 
(lysosomal marker), P-selectin (α-granule marker), and HYAL2. HYAL2 and P-selectin 
were both enriched in fraction number 5, the α-granules fraction; whereas CD42b and 
LAMP-1 were enriched in fractions numbers 2 and 4, respectively. 
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Figure 2.5 (cont.): HYAL2 is stored in a distinct subset of α-granules in resting 
platelets. (C) Confocal microscopy images (maximum projection) of platelets stained for 
HYAL2 (green) and one of the following proteins: CD42b (plasma membrane marker), 
LAMP-2 (dense granule marker), PDI (T-granule marker), KDEL (dense tubular system 
marker), LAMP-1 and NEU1 (lysosomal markers), P-selectin (α-granule marker), vWF 
(α-granule marker), and fibrinogen (α-granule marker). HYAL2 did not co-localize with 
any of the tested markers. Pearson’s correlation coefficients were obtained by analyzing 
individual images (layers) of the Z-stack using Image-Pro Plus software (Rockville, MD). 
Image details for figure 5C: Microscope: Leica TCS SP5 II Confocal/Multi-Photon high 
speed upright microscope (Leica, Germany). Objective: HCX PL APO 63X/1.4NA oil 
immersion. Detector: Leica HyD™ system. Acquisition software: Leica LAS AF 
software (Leica, Germany). Scale bar: 1 µm. 
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Figure 2.5 (cont.): HYAL2 is stored in a distinct subset of α-granules in resting 
platelets. (D) Immuno-electron microscopy images showing resting and activated 
platelets. Washed human platelets were fixed, sectioned, and mounted on formvar-coated 
nickel grids. Ultrathin platelet sections were probed for HYAL2, and the bound antibody 
was labeled with immunogold (10 nm). In resting platelets, HYAL2 appeared to be 
localized within platelet α-granules (black arrows), whereas platelet surface appeared to 
be devoid of any HYAL2. However, in activated platelets, HYAL2 was clearly detected 
on the surface. Image details for figure 5D: Microscope: FEI Tecnai G2 Spirit BioTWIN 
Transmission Electron Microscope (FEI Company, Hillsboro, OR). Camera: Orius 832 
CCD, 11 megapixel. Acquisition software: Digitalmicrograph (Gatan, Inc., Pleasanton, 
CA). Scale bars: 200 nm.  
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2.4.6 Activated platelets have higher HAase activity than non-activated platelets. 
Platelet HYAL2 appeared on the surface of platelets after activation. Therefore, 
we postulated that platelet HAase activity also increases upon activation. We first 
examined whether activated platelets have higher HA degrading ability than non-
activated platelets in the co-culture model. Replicate cultures of polyI:C treated M-SMCs 
were co-cultured with decreasing concentrations (300-10X10
6
/well) of either TRAP-
activated or non-activated freshly isolated platelets. The levels of HA released into the 
media by activated platelets were higher than HA released by non-treated platelets under 
all conditions, suggesting that activated platelets had higher HA degrading ability than 
non-activated platelets (Figure 2.6A). However, below platelet concentration of 
30X10
6
/well,
 
non-treated platelets had no HA-degrading ability, whereas activated 
platelets retained significant levels of activity. We then examined whether activated 
platelets also have higher purified HA degrading activity compared to non-activated 
platelets. TRAP-activated and non-activated platelets were incubated with purified HA 
immobilized to wells of a 96-well plate (pH=3.5). Activated platelets demonstrated 
significantly higher HAase activity (80% maximum) than non-activated platelets (10% 
maximum) (P<0.001). Interestingly, activated platelets also showed significantly higher 
HAase activity than platelet lysates (Figure 2.6B). As expected, activated platelets also 
did not display purified-HA degradaing ability under neutral pH (data not shown).  
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Figure 2.6: Thrombin receptor-mediated platelet activation results in increased 
platelet HAase activity. (A) PolyI:C stimulated human M-SMCs were co-incubated with 
decreasing concentrations of either untreated freshly isolated platelets or TRAP-activated 
platelets for 2 hours at 37°. The amounts of HA released into the media were measured 
by ELISA-like assay. Activated platelets caused a significantly higher increase in HA 
released into the media than non-activated platelets. At a platelet concentration of 
30X10
6
/well, non-activated platelets appeared to have no HAase activity compared to 
activated platelets, which still released significant amounts of HA into media. (**P<.01, 
N=3). 
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Figure 2.6 (cont.): Thrombin receptor-mediated platelet activation results in 
increased platelet HAase activity (B) Freshly isolated untreated or TRAP-activated or 
lysed platelets (3X10
8
/well) were incubated with purified HA immobilized to wells of a 
96-well plate for 18 h at 37°C (pH=3.5). Platelets and digested HA were then washed and 
remaining HA on the wells was detected colorimetrically. Activated platelets 
demonstrated significantly higher HAase activity (80% maximum) than non-activated 
platelets (10% maximum) and platelet lysate (50% maximum) (***P<.001, N=3). 
Maximum activity was achieved by Streptomyces hyaluronidase. 
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2.4.7 IBD patients have lower platelet HYAL2 protein and HAase activities than 
non-IBD controls 
Multiple platelet abnormalities have been identified in patients with IBD, 
including increased numbers and levels of activation [75]. Also, pro-inflammatory HA is 
increased in the inflamed intestinal mucosa of IBD patients. We therefore hypothesized 
that platelet HYAL2 has a role in ECM-HA degradation in IBD and compared the levels 
of platelet HYAL2 and HAase activity in patients with IBD to non-IBD controls. The 
immunoblot assay and HAase assay we used were normalized to total protein because 
IBD patients are known to frequently have high platelet numbers and low platelet 
volume. We first analyzed HYAL2 levels in lysates of platelets from IBD patients 
(N=17) and non-IBD controls (N=13) and found that, interestingly, HYAL2 protein 
levels in IBD patient samples, on average, were 45% lower than samples from non-IBD 
controls (P=0.01) (Figure 2.7A). We then analyzed HAase activity in lysates of platelets 
from IBD patients (N=8) and non-IBD controls (N=8) and found that HAase activity in 
IBD patient samples was also significantly lower than samples from non-IBD controls 
(P<0.001) (Figure 2.7B). 
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Figure 2.7: Platelets from IBD patients have lower HYAL2 and HAase activitity 
than their non-IBD counterparts. Platelets collected from IBD patients and from 
healthy controls, as approved by the Cleveland Clinic Institutional Review Board, were 
washed and lysed. Total protein concentrations of platelet lysates were determined using 
Bradford assay. (A) 25 µg of total protein from each sample was analyzed by 
immunoblotting for HYAL2. Densitometry analysis (ImageQuant TL, GE Healthcare 
Life Sciences, Fairfield, CT) showed that platelets from IBD patients (N=17) displayed 
an average reduction of 45% in HYAL2 protein levels compared to non-IBD controls 
(N=13) (*P=.01). Data are presented as both a scatter plot showing mean and a box-and-
whiskers plot showing median of 10-90 percentiles. 
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Figure 2.7 (cont.): Platelets from IBD patients have lower HYAL2 and HAase 
activitity than their non-IBD counterparts. Platelets collected from IBD patients and 
from healthy controls, as approved by the Cleveland Clinic Institutional Review Board, 
were washed and lysed. Total protein concentration of platelet lysates was determined 
using Bradford assay. (B) Platelet lysates containing 400 µg total protein were analyzed 
for their HAase activity. Platelet lysates were incubated with purified HA immobilized to 
wells of a 96-well plate for 18 h at 37°C (pH=3.5). Lysates and digested HA were then 
washed and remaining HA on the wells was detected colorimetrically. IBD platelets 
demonstrated significantly lower HAase activity (N=8) compared to their healthy 
counterparts (N=8) (***P<.001). Data are presented as both a scatter plot showing mean 
and a box-and-whiskers plot showing median of 10-90 percentiles. 
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2.5. CONCLUSION 
In this report we show that platelets degrade HA from the surfaces of activated 
human intestinal M-SMCs under experimental physiological pH and that this degradation 
can be inhibited by blocking the activity of platelet HYAL2. We also demonstrate that 
platelet degradation of purified HA only occurs under acidic pH, consistent with previous 
reports on HYAL2 activity [92]. Although HYAL2 is known to be a cell surface protein 
[93], we found little evidence of it on the surfaces of resting platelets. Instead, HYAL2 
was detected exclusively on the surfaces of activated platelets. We also show for the first 
time that HYAL2 is packaged within α-granules in resting platelets, and that upon 
activation, HYAL2 is translocated from α-granules to the platelet surface, where it 
functions to digest HA. Finally, we show evidence that patients with IBD have lower 
platelet HYAL2 contents and activity than healthy controls. 
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CHAPTER III 
THE ROLE OF HYALURONAN BINDING PROTEINS AND PLATLET 
ACTIAVTION IN PLATELET-HYALURONAN BINDING 
3.1. ABSTRACT 
Human platelets have the ability to degrade hyaluronan (HA) in the pro-
inflammatory matrix through the activity of HYAL2, which is a GPI-anchored protein 
and one of two enzymes that degrade HA in somatic tissues. Platelet activation plays an 
important role in the expression of HYAL2. Platelet activation causes the immediate 
translocation of HYAL2 from a distinct population of α-granules to platelet surfaces, 
where it exerts its catalytic activity. Importantly, patients with inflammatory bowel 
disease (IBD) have lower platelet HYAL2 levels and activity than healthy controls. 
However, in spite of the facts that platelets cleave HA from surfaces of endothelial and 
smooth muscle cells under cell-culture conditions and purified HA under acidic 
conditions, platelets still cannot degrade purified HA under neutral conditions. We 
hypothesized that HA-binding proteins and platelet activation have a role in facilitating 
the interaction between HA and platelets under experimental neutral conditions. In this 
study, we provide evidence that 1) platelets have the ability to degrade HA released from 
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polyI:C-stimulated cells, in solution; 2) platelet activation results in increased binding of 
platelets to HA; and 3) platelets express the newly discovered HA-binding protein 
KIAA1199 and release it upon activation. In some inflammatory diseases, like IBD, HA 
becomes associated with proteins in the form of cables; in addition, platelets circulate in a 
highly activated state. For those reasons, our data suggest that HA becomes a better 
substrate for platelets degradation under inflammatory conditions. 
3.2. INTRODUCTION 
HA is a non-sulfated, unbranched, glycosaminoglycan and a major component of 
the extracellular matrix. It is present generally in high amounts in many tissues and 
fluids, including the eye vitreous, the umbilical cord, amniotic fluid, and the joints. High 
levels of HA are also present in proliferating tissues and tissues undergoing repair. The 
turnover of HA occurs in a very fast rate in the body. The rapid catabolism of HA, 
through the activity of the hyaluronidase (HYAL) enzymes, represents a major 
mechanism by which HA levels are regulated in the body. HA catabolism is known to be 
dependent upon the classical HA binding receptor CD44 and involves mainly the two 
hyaluronidases: HYAL1 and HYAL2 [18,27-29]. 
Studies have shown that the degradation of HA by HYAL2 is CD44-dependent. 
In human breast tumor cell line, the binding of HA to CD44 activates Rho kinase, which, 
in turn, causes the phosphorylation, and activation, of  Na
+
-H
+
 exchanger (NHE1). The 
activity of NHE1 promotes acidification and creates an acidic extracellular matrix 
environment. The acidic environment provides a condition for HYAL2 to degrade HA at 
the cell surface. In a human embryonic kidney cell line, HYAL1 cannot degrade HA in 
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cells lacking CD44 and that its activity in cells expressing CD44 is primarily 
intracellular. Conversely, the activity of HYAL2 is strictly extracellular but also 
dependent upon CD44, which exists on the cell surface along with HYAL2 [28,29].  
The current accepted model for HA degradation in the somatic tissues of 
vertebrates involves four enzymes: HYAL1, HYAL2, and two β-exoglycosidases. 
Degradation of HA starts at the cell surface. CD44 binds HA extracellularly and mediates 
the process by creating an acidic microenvionment. Then, the acid-active enzyme 
HYAL2 degrades large HA polymers into approximately 20-kDa polymers. These HA 
products get internalized into the lysosomes, where they get degraded by HYAL1 into 
tetra- and hexasaccharides before N-acetyl glucosaminidase and glucuronidase enzymes 
further degrade them into monosaccharides [18]. 
Our group has recently shown that platelets contain HYAL2. We demonstrated 
that after activation, platelets degrade HA in the pro-inflammatory matrix using HYAL2. 
This activation-dependent mechanism results in the immediate translocation of HYAL2 
from α-granules to platelet surfaces, where it exerts its catalytic activity. Importantly, we 
showed that although platelets can cleave HA from surfaces of endothelial and smooth 
muscle cells under cell-culture conditions and purified HA under acidic conditions, they 
cannot degrade purified HA under neutral conditions [89].  
CD44 belongs to a family of glycoproteins that are expressed on the surfaces of 
many cell types, mainly lymphocytes, macrophages, and epithelial cells. In 1994, 
Koshiishi et al. have demonstrated that CD44 is present on mouse megakaryocytes and 
peripheral blood platelets [90]. However, no evidence provided by this group, or any 
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other group, that human platelets express CD44. Our group also was not able to detect 
any CD44 levels in platelets by immunoblotting or immunofuorescence microscopy (data 
not shown). Therefore, HA degradation by platelets under neutral conditions cannot be 
explained by the presence of CD44, and investigating new platelet-HA binding 
mechanisms that do not involve CD44 is crucial to understanding the mechanism by 
which platelets cleave HA.  
In this study, we provide evidence that platelets have the ability to degrade HA 
released from polyI:C-stimulated cells and that platelet activation results in increased 
binding of platelets to HA. Additionally, we show for the first time that platelets express 
the newly discovered HA-binding protein KIAA1199 and release it upon activation. In 
some inflammatory diseases, like IBD, HA becomes associated with proteins to form 
pathological HA structures known as HA cables [51]; in addition, platelets circulate in a 
highly activated state [75]. For those reasons, our data suggest that HA becomes a better 
substrate for platelets degradation under inflammatory conditions. 
3.3. MATERIALS AND METHODS 
3.3.1. Materials 
Fetal Bovine Serum (FBS) from GIBCO Life Technologies, Carlsbad, CA. 100 
µM cell screens were from EMD Millipore, Germany. Acid-Citrate-Dextrose (ACD) was 
from BD Biosciences, Franklin Lakes, NJ. Streptomyces hyaluronidase, Benzonase® and 
prostaglandin E1 were from Sigma Aldrich, St. Louis, MO. Thrombin Receptor 
Activating Peptide (TRAP-6) was from Tocris Bioscience, UK. Anion exchange spin 
columns were from Thermo Scientific, Waltham, MA. Hyaluronan ELISA-like assay was 
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from Echelon Biosceinces, Salt Lake City, UT. Select-HA™ was from Lifecore 
Biomedical, LLC, Chaska, MN. Vectasheild Mounting Medium with DAPI was from 
Vector Labs, Burlingame, CA. 
3.3.2. Cell isolation and culture 
Mucosal intestinal smooth muscle cells (M-SMCs) were isolated from human 
surgical colon specimens obtained within 2 hours after resection (kindly provided by the 
Department of Anatomical Pathology, Cleveland Clinic Foundation, Cleveland, OH). The 
colonic lamina propia (mucosal layer) was isolated and cut into small pieces. The pieces 
were added to Hanks’ BSS containing 0.15% dithiothreitol (w/v) and stirred for 30 
minutes, then washed three times in Hanks’ BSS containing 1 mmol/L EDTA for a total 
time of 3 hours, and finally washed in Hanks’ BSS alone for 2 hours. The pieces of tissue 
were then minced into very small pieces, and incubated for 18 hours in Hanks’ BSS 
containing collagenase and DNase (0.1 mg/ml each), penicillin (250 U/ml), streptomycin 
(250 μg/ml), and fungizone (0.625 μg/ml). After the enzymatic digestion, the released 
cells were filtered from the undigested debris using a 100 µm filter. Cells were then 
cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) and 
antibiotics (penicillin, 100 U/ml; streptomycin, 100 μg/ml; fungizone, 0.25 μg/ml), and 
incubated at 37°C in a 5% CO2 humidified environment. Cultures were washed 
extensively after 48 h to remove non-adherent cells and debris. Confluent cell cultures 
were split at a 1:3 ratio. Cells were used in their first two passages. Cells at 80% 
confluency were treated with growth media containing 50 µg/ml poly:I:C for 20 hours. 
3.3.3. Platelet Isolation 
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Blood was collected by sterile venipuncture (without use of a tourniquet) directly into 
tubes containing Acid-Citrate-Dextrose (ACD) from consented healthy donors as 
approved by the Cleveland Clinic Institutional Review Board.  The citrated blood was 
centrifuged for 20 min at 200g without breaking. The Platelet-Rich Plasma (PRP) layer 
was then collected, prostaglandin E1 was added to a final concentration of 35 ng/ml, and 
the PRP centrifuged for 20 min at 600g. The resulting platelet pellet was then washed 
twice with HBSS containing 35 ng/mL PGE1. 
3.3.4. HA Agarose Gel Electrophoreses 
Isolated and washed human platelets were resuspended in RPMI media + 2% FBS 
(300X10
6
/ml) and incubated with or without each of the following: Poly:I:C treated 
SMCs , HA released from poly:I:C treated cells in solution and purified HA (1000 kDa) 
in solution for 1 hour at 37ºC. Cell layer was collected by digesting with trypsin. After 
this step all samples were treated the same for HA isolation. Samples were treated with 
0.5 µg/ml proteinase K for 18 hours at 60ºC. Samples were then treated with DNase and 
RNase and concentrated using a speed vac. Samples were then dialysed against water and 
were subjected to anion exchange spin columns. Samples were made into 0.1 M NaCl 
then added to the spin columns. Columns were washed with 0.1 and 0.4 M NaCl. HA was 
eluted with 0.8 M NaCl. Samples were dialyzed against water and concentrated and 
applied to 0.5% agarose gel. Electrophorsis was carried at 60V for 4 hours. Gels were 
stained with 0.005% StainsAll in 50% ethanol and destained with 10% ethanol and light 
exposure [86]. 
3.3.5. Immunohistochemical staining of platelets 
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Freshly isolated platelets were fixed in 3.5% paraformaldehyde for 30 min at RT. 
Fixed platelets were spun onto a poly-l-lysine coated 8-well chamber slide at 250g for 10 
min. Permeablization of platelets was done by adding cold methanol for 5 min. Fixed 
Specimens were incubated with blocking buffer (2% FBS in HBSS) for 1 h. Specimens 
were incubated with a rabbit polyclonal antibody against KIAA1199 (ProteinTech, 
Chicago, IL) overnight. After washing, specimens were incubated with the 568 Alexa 
Fluor® anti-rabbit secondary antibody for 45 min at RT. Specimens were washed again 
and Vectashield Mounting Medium with DAPI was added. Images were obtained using 
Leica upright microscope DM5500 B (Leica, Germany).  
3.3.6 Flow Cytometry 
Freshly isolated resting platelets were fixed in 1% paraformaldehyde for 2 h at 
RT. For permeablization and intracellular staining, fixed platelets were further incubated 
with 0.5% saponin. Platelets were washed then incubated for 1 h at RT in flow cytometry 
buffer (0.1% BSA, 0.05% sodium azide in PBS) with anti-KIAA1199 (ProteinTech) 
(1:100) and anti-CD16/CD32 (to block the Fc receptors, 1:100). Platelets were washed 
then incubated with Alexa Fluor® 568 Goat Anti-Rabbit IgG for 30 min at RT. 30,000 
events/sample were acquired on a BD Bioscience LSR II (BD Biosciences) flow 
cytometer. Data was analyzed using FlowJo (Tree Star, Ashaland, OR). 
3.3.7. Platelet microparticles and releasate isolation 
Platelet microparticles and releasates were isolated as previously described [84]. 
Briefly, freshly isolated platelets were incubated without or with 15 μM TRAP for 10 
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minutes at 37°C and centrifuged at 750g for 20 minutes (platelet fraction). The 
supernatant platelet releasates were placed on ice and centrifuged at 10,000g for 30 
minutes at 4°C to obtain the microparticles fraction. Platelet fractions (750g pellet), 
microparticle fractions (10
4
 pellet), and platelet releasates (10
4
 g supernatant) were 
analyzed by western blotting for the presence of KIAA1199. 
3.4. RESULTS AND DISCUSSION 
3.4.1. Platelets digest HA released from poly:I:C-stimulated M-SMCs, but not 
purified HA, in solution. 
We previously demonstrated that platelets can digest HA from surfaces of 
activated endothelium, which produces fragmented HA capable of promoting cellular 
responses [77]. We also showed that platelets cleave HA from the surfaces of activated 
mucosal intestinal smooth muscles cells (M-SMCs) [89]. Importantly, we demonstrated 
that platelet-degradation of HA on the surfaces of activated cells occurs through the 
activity of HYAL2 [89]. HYAL2 is reported to be an acid active enzyme [23]. However, 
we showed that degradation of purified HA by platelets and platelet lysates only occurs 
under acidic conditions, with a peak activity at pH of 3.5. We therefore hypothesized that 
activated M-SMC-associated HA has a unique property that allows it to be degraded by 
platelets. To test this hypothesis, we stimulated M-SMCs with poly:I:C for 18 hours to 
induce pathological HA cable formation. Then, we replaced media and allowed M-SMCs 
to release their HA for 4 hours. Following incubation, we collected the released HA and 
incubated it with platelets for 4 hours at 37°C. As controls, we incubated platelets with 
poly:I:C stimulated M-SMCs and with purified HA in solution. Isolated HA was 
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analyzed by agarose gel electrophoresis. As expected, under neutral pH, platelets 
degraded HA from surfaces of activated M-SMCs and did not degrade purified HA in 
solution. Importantly, however, platelets degraded M-SMC-HA in solution under neutral 
pH (figure 3.1). Our data suggest a role for either HA binding proteins, HA tertiary 
structure, or both in facilitating the fragmentation reaction. This implies that HA becomes 
a better substrate for platelet degradation under inflammatory conditions because the 
main difference between purified HA and pathological HA matrices is that pathological 
HA, which is also highly leukocyte adhesive, is associated with HA-binding proteins 
such as IαI heavy chains and versican. 
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Figure 3.1: Platelets degrade cell-released HA in solution. Agarose gel electrophertic 
analysis of HA before (lanes 1,3,&5) and after (lanes 2,4,&6) incubation with platelets. 
Whereas commercial purified HMWHA was not degraded by platelets in solution (lanes 
5&6), HA released from poly:I:C-treated cells was degraded by platelets at 37ºC in a cell-
free environment (lanes 3&4). As a positive control, platelets were incubated with M-
SMCs and were able to degrade HA from the surfaces of these cells (lanes 1&2). All 
incubations were carries at pH 7.4. 
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3.4.2. Platelet activation results in increased platelet-HA binding. 
 We showed previously that platelet HYAL2 is stored inside α-granules in resting 
platelets. However, upon activation by a thrombin receptor stimulator, platelet HYAL2 
becomes surface expressed, as determined by flow cytometry and immunoelectron and 
immunofluorescence microscopy. Importantly, platelet activation results in a significant 
increase in platelet HAase activity, whether the substrate is cell-surface HA or purified 
HA. We also observed when we blocked platelet HYAL2, platelets retained the ability to 
bind HA cables, without cleaving them [89]. Collectively, we hypothesized that not only 
does platelet activation have a role in platelet HAase activity, but also it has a role in 
platelet-HA binding. To test this hypothesis, we incubated fluorescein isothiocyanate 
(FITC)-labeled HA with resting and activated platelets. We then measured HA binding to 
platelets by measuring platelet surface-fluorescence intensity by flow cytometry. We 
found that resting platelets demonstrated low levels of binding to HA. However, the 
binding ability of activated platelets to HA was significantly higher (figure 3.2). Upon 
vascular injury, activated platelets adhere to the proteins of the exposed connective 
tissues. HA is a major component of the extravascular connective tissues. Therefore, our 
data provide evidence that HA also represents a substrate for activated platelet binding, 
probably through a HA binding protein that becomes expressed on the surfaces of 
platelets upon activation. 
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Figure 3.2: Activated platelets have higher affinity to HA than resting platelets. The 
figure shows flow cytometry analysis of mean fluorescence intensity on platelet surfaces 
upon the incubation of platelets with FITC-labaled HA. Although resting platelets 
showed binding affinity to HA, TRAP-activated platelets demonstrated significantly 
higher HA-binding ability to HA.  
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3.4.3. Platelets express the novel HA-binding protein KIAA1199. 
Platelets and their megakaryotic precursors express the enzyme HYAL2 [77]. 
Importantly, we showed that platelets use their HYAL2, after they become activated, to 
cleave HA from the surfaces of mucosal intestinal endothelial and smooth muscles cells 
[77,89]. Additionally, we showed that platelets can bind HA and that this binding activity 
increases significantly when platelets are activated with a thrombin receptor stimulator. 
However, how platelets bind HA is still unclear, and little evidence exists that the classic 
HA receptor CD44 is expressed on human platelets. Therefore, we wanted to investigate 
the possibility that platelets express a different HA-binding protein. We tested whether 
platelets express the novel protein KIAA1199, which has just been recently identified as 
a HA-binding protein that contributes to HA degradation [30]. Using an immunoblotting 
assay, we found that platelets express KIAA1199, which appeared as a band at the 
expected molecular weight of 150 kDa. We used two different antibodies that recognize 
two different amino acid sequences (aa 31-386 and aa 880-890) to eliminate the 
possibility of non-specific binding (figure 3.3A). Interestingly, both antibodies 
recognized other bands with smaller sizes, which might represent cleaved forms of 
KIAA1199. We also confirmed that platelets express KIAA1199 using 
immunofluorescence microscopy (figure 3.3B). The presence of KIAA1199 in platelets 
may assist in defining a novel mechanism by which platelets bind HA. 
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Figure 3.3: Platelets express KIAA1199. (A) immunoblot analysis of platelet lysates for 
the presence of KIAA1199. Platelets express the 150 kDa-sized KIAA1199. The 
presence of KIAA1199 was confirmed using two different antibodies: antibody 1 (Ab1) 
recognizes amino acids 880-890, whereas antibody 2 (Ab2) recognizes amino acids 31-
386. The smaller bands may be indicative of cleaved forms of KIAA1199. 
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Figure 3.3 (cont.): Platelets express KIAA1199. (B) Immunofluorescence analysis of 
KIAA1199 (red) expression in platelets. Platelets were fixed and centrifuged onto poly-l-
lysine-coated slides. After blocking, platelets were incubated with or without (2º ab only 
control) an antibody against KIAA1199, washed, and incubated with 568 Alexa 
secondary antibody. KIAA1199 expression in platelets appears to be granular, suggesting 
its storage inside platelet granules. 
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3.4.4. Platelets express KIAA1199 intracellularly and release it upon activation.  
Platelet HYAL2 degrades HA from the surfaces of activated intestinal mucosal 
cells [89]; however, the mechanism by which platelets bind HA is still unclear. We 
provided evidence that platelet-HA binding increases significantly when platelets become 
activated. We also showed by immunoblotting and immunofluorescence microscopy that 
KIAA1199, which is a novel HA-binding protein and a contributor to HA degradation, is 
expressed by platelets. KIAA1199 has been reported to be localized inside endoplasmic 
reticulum in cancer cells [91]. We wanted to investigate whether platelet KIAA1199 is 
expressed intracellularly or extracellularly. Furthermore, we wanted to investigate how 
platelet activation affects platelet KIAA1199 localization. Activated platelets release 
numerous adhesive and clotting proteins from their granular stores to the surrounding 
environment. These molecules can be soluble, associated with the platelet surface, or 
packaged in microparticles [59]. When we analyzed platelet surface expression of 
KIAA1199 by flow cytometry, there was little to no KIAA1199 expression detected. 
However, when we permeablized platelets, we were able to detect KIAA1199 by flow 
cytometry (figure 3.4A), which suggests that KIAA1199 is stored intracellularly in 
resting platelets. To investigate the role of platelet activation in the expression of platelet 
KIAA1199, we activated platelets for 10 minutes using TRAP and isolated their 
microparticles and soluble releasate. We found that KIAA1199 is completely released 
upon activation, but does not become part of microparticles (figure 3.4B). Our data 
suggest that KIAA1199 is a soluble protein that platelets release immediately after 
activation. However, the role of platelet KIAA1199, and specifically its role in HA 
binding and depolymerization, is still unclear. Defining the role of platelet-released 
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KIAA1199 may reveal a novel mechanism by which platelets interact with the 
extracellular matrix of exposed tissues and a possibly role of platelet in inflammatory 
diseases, especially IBD. 
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Figure 3.4: Platelets express KIAA1199 intracellularly. (A) Flow cytometry analysis 
of surface and intracellular KIAA1199. No KIAA1199 is detected on the surfaces of 
resting, non-permeabilized platelets. However, significant levels of KIAA1199 staining 
were obtained in permeablized platelets, suggestive of intracellular localization of 
KIAA1199 in resting platelets.  
98 
 
 
 
Figure 3.4 (cont.): KIAA1199 becomes part of platelet releasate upon activation. (B) 
Western blot analysis of KIAA1199. Platelets were activated with TRAP for 10 minutes 
before they were centrifuged at 750 g to collect platelet pellet. Supernatant was then 
centrifuged at 10,000 g to collect platelet microparticles.  Lanes: (1) non-activated 
platelet lysate , (2) activated platelet lysate (pellet + supernatant), (3) activated platelets 
only (750 g pellet), (4) microparticles (10,000 g pellet), (5) platelet releasate (10,000 g 
supernatant).  
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CHAPTER IV 
DISCUSSION, FUTURE DIRECTIONS, AND CONCLUDING REMARKS 
 
4.1. DISCUSSION 
In this study, we showed that platelets degrade HA from the surfaces of activated 
human intestinal mucosal smooth muscle cells under experimental physiological pH and 
that this degradation is HYAL2-dependent because blocking HYAL2 abrogated the 
degradation activity. We also demonstrated that platelet cleavage of purified HA only 
occurs under acidic pH, which is consistent with previous reports on HYAL2 activity 
[92]. We found little evidence of HYAL2 on the surfaces of resting platelets, although 
HYAL2 is known to be a cell surface protein [93]. Instead, HYAL2 was detected 
exclusively on the surfaces of activated platelets. Importantly, we showed that HYAL2 is 
packaged within a distinct subpopulation of α-granules in resting platelets, and that upon 
activation, it gets translocated from α-granules to the platelet surface. While HYAL2 is 
on platelet surface, it functions to digest HA. We also demonstrated a clinical relevance 
for platelet HYAL2. We showed evidence that patients with IBD have lower platelet 
HYAL2 contents than their healthy controls. Additionally, platelets from IBD patients 
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demonstrated lower hyaluronidase activity than platelets from healthy controls. We also 
showed in this report that platelets, under neutral experimental conditions, have the 
ability to degrade HA released from activated mucosal intestinal smooth muscle cells, but 
not purified HA and that activated platelets have significantly increased binding affinity 
to HA in comparison to resting platelets. Finally, we demonstrated that platelets express 
the newly discovered HA-binding protein KIAA1199 and release it upon activation.  
Our data raise several interesting questions. The observation that platelets degrade 
cell surface-HA but not purified HA under physiological pH suggests that platelet-
mediated HA degradation depends upon multiple factors and is likely a regulated process. 
HYAL2 is reported to be an acid active enzyme [23]. However, it was demonstrated, in 
an embryonic kidney cell line, that HYAL2 becomes active under physiological pH only 
when it coexists with CD44 at the plasma membrane [29]. Another group has shown, in a 
breast cancer line, that the CD44-dependent HA degradation was achieved due to an 
increase in the activity of the sodium-hydrogen exchanger NHE1, causing a local drop in 
pH, which creates an acidic microenvironment for HYAL2 [28]. This is an unlikely 
scenario in platelets because intact platelets, either resting or activated, did not degrade 
purified HA under neutral pH. Additionally, there is no evidence that human platelets 
express CD44. In our lab, platelet degradation of HA was not inhibited when we pre-
incubated platelets with anti-CD44 antibodies (data not shown). In our cell co-culture 
model, a likely scenario is that HA binding proteins (e.g., versican, pentraxin 3, TSG6, 
and the heavy chains of inter-α-trypsin inhibitor) [94,95] may be necessary to facilitate 
the interaction between platelets and HA and therefore mediate HA catabolism by 
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platelets. This is similar to the requirements our group has noted for non-activated 
leukocyte binding to HA cables [51].  
Another possible non-CD44-dependent mechanism by which platelets degrade 
HA under neutral pH is by the involvement of a platelet HA receptor or binding protein 
in assisting HYAL2 to degrade HA. A good candidate is KIAA1199, which is a newly 
identified HA binding protein that specifically contributes to HA degradation. We 
investigated whether platelets express KIAA1199 and found that platelets have 
KIAA1199 and store it intracellularly. However, platelets completely release KIAA1199 
after they are activated. Additionally, we found that activated platelets have significantly 
higher binding affinity to HA than non-activated platelets. In some inflammatory 
diseases, like IBD, HA becomes associated with proteins to form pathological HA 
structures known as HA cables; in addition, platelets circulate in a highly activated state. 
For those reasons, our data suggest that HA becomes a better substrate for platelet 
degradation under inflammatory conditions. 
Another interesting point our data raises is that HYAL2 is stored in a distinct 
subpopulation of α-granules, which lacks three known α-granule markers: P-selectin, 
vWF, and fibrinogen. Selective packaging of proteins within different subpopulations of 
α-granules in platelets has been a matter of controversy [96,97]. For example, vascular 
endothelial growth factor, a pro-angiogenic protein, was shown to be stored in a different 
α-granule population than endostatin, an anti-angiogenic protein [62]. Conversely, it has 
been proposed that random distribution of proteins into α-granules occurs [98]. However, 
the clear localization of HYAL2 within α-granules, observed by electron microscopy and 
sucrose density gradient analysis, and the complete lack of co-localization between 
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HYAL2 and P-selectin, a protein thought to be present in all α-granules [62], favor the 
hypothesis that α-granule proteins can be separated into distinct subpopulations.  
Under healthy conditions, platelets do not adhere to the vascular wall. However, 
upon vascular injury, platelets are exposed to components of extracellular matrix (e.g. 
collagen and fibronectin), to which they rapidly adhere [99]. We have reported previously 
that platelets can bind and degrade HA from the surfaces of activated endothelial cells 
[77]. Here we show that HA in the extracellular matrix of polyI:C treated M-SMCs can 
also be degraded by platelets. This is important because HA is upregulated during 
inflammation in many tissues, and smooth muscle cells and myofibroblasts are 
considered to be the major HA producing cells. High levels of HA deposition have been 
reported in several inflammatory diseases including asthma, arithritis and hepatitis [44]. 
Our group, in addition, has reported an upregulation of HA in the intestines of patients 
with IBD, a chronic condition characterized by tissue erosion and intestinal bleeding [43].
 
IBD is also associated with platelet dysfunction [75]. Multiple platelet 
abnormalities have been identified in patients with IBD including reactive 
thrombocytosis, low mean platelet volume and increased density [71-75]. Importantly, 
platelets in IBD patients circulate the periphery in an increased activated state and are 
more susceptible to activation than platelets from healthy subjects [71]. Here, we present 
yet another abnormality associated with platelets from patients with IBD.  
4.2. FUTURE DIRECTIONS 
The hypothesis that HA binding proteins that are part of HA cables under 
inflammatory conditions facilitate the interaction between platelets and HA needs to be 
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further investigated because not only can it explain how platelets bind HA, but also how 
other immune cells, like leukocytes, bind HA. A good strategy would be to test whether 
proteinase K-treated pathological HA structures, which are released into cultured media 
of poly:I:C-stimulated smooth muscle cells, can be degraded by platelets in solution. 
Furthermore, these pathological HA structures can be purified and the identity of HA 
binding proteins can be determined by mass spectrometric analysis. Identifying the 
specific HA-binding protein that facilitates the interaction between platelets and HA can 
be crucial to understanding the conditions under which platelets bind and degrade HA. 
Also, because we found that HYAL2 is an α-granule protein that does not 
colocalize with any known classical α-granule protein, we concluded that HYAL2 is 
stored in a distinct subpopulation if α-granules. Further research, however, is needed to 
define the contents of the HYAL2-containing α-granules and to determine whether any 
functional coclustering of proteins within these granules exists. One approach to 
investigate the contents of HYAL2-containing α-granules would be to isolate these 
specific granules using a HYAL2 antibody bound to protein-A-coated magnetic beads. 
After the granules are purified, they can be lysed and their contents can be determined by 
mass spectrometry. It would be interesting to know whether KIAA1199 is located inside 
these granules along with other possible HA binding proteins or receptors. Furthermore, 
the possibility that HYAL2 binds to KIAA1199 needs to be investigated, possibly by 
performing co-immunoprecipitation experiments.  
On the other hand, it might be critical to further investigate the hypothesis that 
platelet HYAL2 has a role in IBD. IBD is a very complex disease and understanding the 
role of platelets in its pathogenesis might provide new directions on how to treat the 
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disease. One method to investigate the role of platelet HYAL2 in IBD is to induce colitis 
in a HYAL2-knowckout mouse and study the pathology and progression of the disease in 
this mouse model. It also might be important to determine whether transfusing platelets 
from wild-type mice into the colitis HYAL2-knockout mice results in faster recovery. 
Finally, because most currently used methods to diagnose IBD are invasive, investigating 
the possibility of using low platelet HYAL2 and activity as biomarkers for IBD may be 
important in the diagnosis of this enigmatic disease. 
4.3. CONCLUDING REMARKS 
Studies on the interaction between platelets and the ECM have been limited to the 
interaction between platelets and ECM proteins, including collagen and fibrinogen. Here, 
we present a novel mechanism by which platelets interact with ECM; we show that 
platelets can interact also with a polysaccharide component of the ECM, which is HA. 
This interaction may be crucial to the pathogenesis of IBD and possibly other 
inflammatory diseases. Figure 41 shows how low platelet HYAL2 and HAase activity 
might have a role in the pathogenesis of IBD. One possibility is that the lack of HYAL2 
in platelets might be contributing to intravascular microthrombi formation, a feature 
widely observed in IBD [100]. This major abnormality in IBD mucosa is characterized by 
the presence of platelet thrombi cross-linked with fibrin in the mucosal microvasculature. 
Interestingly, it has been reported that HA can tightly bind fibrinogen [101,102]; in 
addition, there is a significant increase in HA deposition in tissues of IBD patients [43]. 
Collectively, HYAL2 might be necessary to degrade HA and therefore prevent thrombus 
formation.  
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We previously showed that the accumulating pathological HA in the tissues of 
IBD patients has the ability to bind and recruit leukocytes [51], which, in turn, can secrete 
various inflammatory cytokines. Low platelet HYAL2 might allow for increased 
accumulation of HA, resulting in increased number of leukocytes recruited. Cytokines 
release by leukocytes may create a chronic condition in IBD by stimulating vascular cells 
to produce more pathological HA cables, which, in turn, bind more leukocytes creating a 
cycle of inflammation.  
Another mechanism by which HYAL2 might be contributing to IBD is its 
possible role in wound healing. Ulceration due to severe inflammation is a major feature 
in IBD and can cause damage to blood vessels. HA sharply accumulates during the 
inflammation phase of wound healing and impaired clearance of HA may result in 
enduring inflammation [103]. As a result, HA degradation by platelet HYAL2 might be 
crucial for proper tissue repair upon injury. Furthermore, HA fragments generated by 
platelet HYAL2 may have a role in improving wound healing [104]. All of these 
functions (the prevention of microthrombi formation, the prevention of leukocyte 
recruitment, and wound healing) could be impaired in IBD patients with low platelet 
HYAL2. 
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Figure 41. Low platelet HYAL2 contributes to IBD pathogenesis. Low platelet 
HYAL2 may contribute to IBD pathogenesis by three different ways: 1) Low platelet 
HYAL2 results in increased HA accumulation. The ability of platelets to bind HA and 
fibrinogen, in addition to the ability of HA to bind fibrinogen, may result in microthrombi 
formation, typically observed in tissues of patients with IBD; 2) Low platelet HYAL2 
results in increased HA cables that can bind leukocytes, which produce cytokines that 
create an inflammation cycle; 3) Low platelet HYAL2 results in increased HA 
accumulation and decreased HA fragments. Both of which may result in impaired wound 
healing. 
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